{"content":"<li class=\"n-box-item date-title\" data-end=\"1513227599\" data-start=\"1513141200\" data-txt=\"Monday, December 23, 2019\">Wednesday, December 13, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3318190\" data-ts=\"1513223382\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IMUC\" target=\"_blank\">IMUC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318190-immunocellular-therapeuticsplus-158-on-immuno-oncology-milestone\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ImmunoCellular Therapeutics +158% on immuno-oncology milestone</a></h4><ul>     <li>ImmunoCellular Therapeutics (<a href='https://seekingalpha.com/symbol/IMUC' title='ImmunoCellular Therapeutics, Ltd.'>OTCPK:IMUC</a>) <font color='green'>+158%</font> after-hours on news it <a href=\"https://seekingalpha.com/pr/17026487-immunocellular-therapeutics-achieves-key-milestone-stem-t-cell-research-immuno-oncology\" target=\"_blank\">achieved a key milestone</a> in its research-stage Stem-to-T-Cell immuno-oncology program.</li>     <li>IMUC says the milestone represents an important step toward stimulating the patient's immune system to produce an unlimited supply of killer T cells that specifically target and destroy tumor cells with minimal side effects, which could prove effective in treating many types of cancers.</li>     <li>IMUC says its stem cell technology has the potential for meaningful advantages over other novel immuno-oncology technologies, including use in combination approaches, and it is exploring potential collaborations for its clinical programs and other strategic alternatives.</li></ul><div class=\"tiny-share-widget\" data-id=\"3318190\" data-linked=\"ImmunoCellular Therapeutics +158% on immuno-oncology milestone\" data-tweet=\"$IMUC - ImmunoCellular Therapeutics +158% on immuno-oncology milestone https://seekingalpha.com/news/3318190-immunocellular-therapeuticsplus-158-on-immuno-oncology-milestone?source=tweet\" data-url=\"https://seekingalpha.com/news/3318190-immunocellular-therapeuticsplus-158-on-immuno-oncology-milestone\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:49 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318186\" data-ts=\"1513211630\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARGX\" target=\"_blank\">ARGX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318186-argenx-raises-231m-in-upsized-public-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Argenx raises $231M in upsized public offering</a></h4><ul>   <li>Argenx (NASDAQ:<a href='https://seekingalpha.com/symbol/ARGX' title='Argenx SE'>ARGX</a>) has <a href=\"https://seekingalpha.com/pr/17026664-argenx-raises-approximately-231-million-gross-proceeds-upsized-u-s-public-offering\" target=\"_blank\">raised about $231M</a> after upsizing a public offering today.</li>    <li>The company sold 4.44M ADS, up from a total it <a href=\"https://seekingalpha.com/news/3318019-argenx-updates-public-offering-upto-3_5m-adss-u-s\" target=\"_blank\">raised to 3.5M</a> earlier, at $52 each.</li>    <li>Underwriters still have a 30-day option to buy up to 15% more (666,000 ADS) at the offering price.</li>    <li>Shares <font color='red'>declined 4.1%</font> on Nasdaq today to close at $52.73.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3318186\" data-linked=\"Argenx raises $231M in upsized public offering\" data-tweet=\"$ARGX - Argenx raises $231M in upsized public offering https://seekingalpha.com/news/3318186-argenx-raises-231m-in-upsized-public-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3318186-argenx-raises-231m-in-upsized-public-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:33 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318173\" data-ts=\"1513204604\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318173-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers:</b> <a href='https://seekingalpha.com/symbol/BAND' title='Bandwidth, Inc.'>BAND</a> <font color='green'>+11.2%</font>. <a href='https://seekingalpha.com/symbol/NDSN' title='Nordson Corporation'>NDSN</a> <font color='green'>+9.5%</font>. <a href='https://seekingalpha.com/symbol/GLUU' title='Glu Mobile Inc.'>GLUU</a> <font color='green'>+5.8%</font>. <a href='https://seekingalpha.com/symbol/LITE' title='Lumentum Holdings Inc.'>LITE</a> <font color='green'>+3.2%</font>. <a href='https://seekingalpha.com/symbol/BSBR' title='Banco Santander &#40;Brasil&#41; S.A.'>BSBR</a> <font color='green'>+2.2%</font>.</li><li><b>Top losers:</b> <a href='https://seekingalpha.com/symbol/PIR' title='Pier 1 Imports Inc.'>PIR</a> <font color='red'>-22.6%</font>. <a href='https://seekingalpha.com/symbol/ABM' title='ABM Industries Incorporated'>ABM</a> <font color='red'>-9.9%</font>. <a href='https://seekingalpha.com/symbol/TNTR-OLD' title='Tintri, Inc.'>TNTR-OLD</a> <font color='red'>-5.6%</font>. <a href='https://seekingalpha.com/symbol/VCO-OLD' title='Vina Concha y Toro S.A. &#40;ADR&#41;'>VCO-OLD</a> <font color='red'>-4.3%</font>. <a href='https://seekingalpha.com/symbol/TECK' title='Teck Resources Limited'>TECK</a> <font color='red'>-2.1%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3318173\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$BAND $NDSN $GLUU - After Hours Gainers / Losers https://seekingalpha.com/news/3318173-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3318173-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318172\" data-ts=\"1513204118\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FOX\" target=\"_blank\">FOX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318172-wsj-disney-fox-deal-value-fox-whole-over-40-share\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">WSJ: Disney/Fox deal would value Fox as a whole over $40/share</a></h4><ul>   <li>The deal now expected to arrive tomorrow that hands many of the entertainment assets of Twenty-First Century Fox (<a href='https://seekingalpha.com/symbol/FOX' title='Twenty-First Century Fox, Inc.'>FOX</a>, <a href='https://seekingalpha.com/symbol/FOXA' title='Twenty-First Century Fox, Inc.'>FOXA</a>) to Walt Disney (NYSE:<a href='https://seekingalpha.com/symbol/DIS' title='The Walt Disney Company'>DIS</a>) is coming at a price that <a href=\"https://www.wsj.com/articles/disney-finalizing-pact-to-acquire-assets-from-21st-century-fox-1513203075\" target=\"_blank\">values Fox as a whole</a> at just over $40/share.</li>    <li>Disney's not taking all of Fox -- Fox would retain its news operations, Fox Sports 1 and its broadcast network -- but it would be paying about $29/share to Fox for the media assets it wants.</li>    <li>That news has <a href='https://seekingalpha.com/symbol/FOXA' title='Twenty-First Century Fox, Inc.'>FOXA</a> on the move after hours: <font color='green'>up 1.4%</font> to $33.20. <a href='https://seekingalpha.com/symbol/FOX' title='Twenty-First Century Fox, Inc.'>FOX</a> is <font color='green'>up 2.8%</font> to $33.25. Disney is flat in postmarket trading so far.</li><li>The deal's expected to be all stock, with Disney assuming some Fox debt in the process.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3318032-cnbc-disney-fox-asset-deal-seen-60b\" target=\"_blank\">CNBC: Disney-Fox asset deal seen at $60B</a> (Dec. 13 2017)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3317746-cnbc-disney-glide-path-thursday-fox-asset-deal\" target=\"_blank\">CNBC: Disney on 'glide path' for Thursday Fox asset deal</a> (Dec. 12 2017)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3318172\" data-linked=\"WSJ: Disney/Fox deal would value Fox as a whole over $40/share\" data-tweet=\"$FOX $FOX $FOXA - WSJ: Disney/Fox deal would value Fox as a whole over $40/share https://seekingalpha.com/news/3318172-wsj-disney-fox-deal-value-fox-whole-over-40-share?source=tweet\" data-url=\"https://seekingalpha.com/news/3318172-wsj-disney-fox-deal-value-fox-whole-over-40-share\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:28 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>34&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318161\" data-ts=\"1513201768\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PBYI\" target=\"_blank\">PBYI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318161-emas-oncology-advisory-group-to-render-opinion-on-puma-bios-neratinib-next-month-shares-slip\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">EMA&#39;s oncology advisory group to render opinion on Puma Bio&#39;s neratinib next month; shares slip 2% after hours</a></h4><ul><li>Puma Biotechnology (NYSE:<a href='https://seekingalpha.com/symbol/PBYI' title='Puma Biotechnology, Inc.'>PBYI</a>) eases&nbsp;<font color='red'>2%</font>&nbsp;after hours on light volume in response to its <a href=\"https://seekingalpha.com/pr/17026524-puma-biotechnology-announces-meeting-scientific-advisory-group-oncology-europe-review\" target=\"_blank\">announcement </a>that the European Medicines Agency &#40;EMA&#41; has asked the Scientific Advisory Group on Oncology to provide an opinion on the clinical data supporting the company's marketing application seeking approval for neratinib for the extended adjuvant treatment of early-stage HER2-positive breast cancer in patients previously treated with a regimen containing Roche's Herceptin (trastuzumab). The group will meet on January 11, 2018.</li><li>The EMA accepted the application for review on August 22. The company says it will respond to the Day-180 List of Outstanding Issues by December 22.</li><li>The normal EMA review period is 210 days so an opinion by the Committee for Medicinal Products for Human Use &#40;CHMP&#41; should be issued on or about March 20, 2018.</li></ul><div class=\"tiny-share-widget\" data-id=\"3318161\" data-linked=\"EMA&#39;s oncology advisory group to render opinion on Puma Bio&#39;s neratinib next month; shares slip 2% after hours\" data-tweet=\"$PBYI - EMA&#39;s oncology advisory group to render opinion on Puma Bio&#39;s neratinib next month; shares slip 2% after hours https://seekingalpha.com/news/3318161-emas-oncology-advisory-group-to-render-opinion-on-puma-bios-neratinib-next-month-shares-slip?source=tweet\" data-url=\"https://seekingalpha.com/news/3318161-emas-oncology-advisory-group-to-render-opinion-on-puma-bios-neratinib-next-month-shares-slip\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:49 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318155\" data-ts=\"1513200825\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TNTR-OLD\" target=\"_blank\">TNTR-OLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318155-tintriminus-9-on-weak-q3-downside-guidance-and-strategic-option-talks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tintri -9% on weak Q3, downside guidance, and strategic option talks</a></h4><ul><li>        Tintri (NASDAQ:<a href='https://seekingalpha.com/symbol/TNTR-OLD' title='Tintri, Inc.'>TNTR-OLD</a>) shares are&nbsp;<font color='red'>down 9%</font>&nbsp;aftermarket following Q3 results that met EPS estimates but missed on revenue. Downside Q4 guidance has revenue from $25M to $27M (consensus: $42.89M) and EPS from -$0.83 to -$0.79 (consensus: $-0.68).</li><li>               CEO Ken Klein expresses disappointment with Q3 revenue and says the company was impacted by delayed and reduced purchases but some of those delayed transactions closed last month.&nbsp;</li><li>               Klein: &ldquo;We are exploring strategic options available to the company to deliver value to our stockholders, including retaining investment bank advisors to assist us in this process and optimizing our operating model to reduce our cash burn rate and shorten the time to generate positive cash flow.&rdquo;&nbsp;</li><li>               <a href=\"https://seekingalpha.com/pr/17026496-tintri-reports-third-quarter-fiscal-2018-financial-results\" target=\"_blank\">Press release</a>&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3318131-tintri-eps-line-misses-revenue\" target=\"_blank\">Tintri EPS in-line, misses on revenue</a> (Dec. 13)</li></ul><div class=\"tiny-share-widget\" data-id=\"3318155\" data-linked=\"Tintri -9% on weak Q3, downside guidance, and strategic option talks\" data-tweet=\"$TNTR-OLD - Tintri -9% on weak Q3, downside guidance, and strategic option talks https://seekingalpha.com/news/3318155-tintriminus-9-on-weak-q3-downside-guidance-and-strategic-option-talks?source=tweet\" data-url=\"https://seekingalpha.com/news/3318155-tintriminus-9-on-weak-q3-downside-guidance-and-strategic-option-talks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:33 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318154\" data-ts=\"1513200752\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BAND\" target=\"_blank\">BAND</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318154-bandwidthplus-10_2-first-public-report-shows-revenue-growth\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bandwidth +10.2% as first public report shows revenue growth</a></h4><ul>   <li>Bandwidth (NASDAQ:<a href='https://seekingalpha.com/symbol/BAND' title='Bandwidth, Inc.'>BAND</a>) is <font color='green'>up 10.2%</font> after hours following its release of <a href=\"https://seekingalpha.com/news/3318129-bandwidth-beats-0_06-beats-revenue\" target=\"_blank\">Q3 earnings</a>, its first report since starting trading Nov. 10.</li>    <li>Revenues grew steadily and gross profit ticked up to $19.9M (non-GAAP basis) from a year-ago $18.3M. Gross margin rose to 48% from 47%.</li>    <li>Net income dipped slightly, to $2.2M (non-GAAP) from a year-ago $3.7M. EBITDA of $5.2M beat an expected $4.2M.</li>    <li>Active CPaaS customers were 918, up 18% Y/Y as of Sept. 30. Dollar-based net retention rate was 105% vs. a year-ago 112% mainly due to a \"decision to curtail services to a competitor.\"</li>    <li>Cash and equivalents were $5.4M, with $38.5M in debt as of Sept. 30; the Nov. 14 IPO generated $74.4M, some of which was used to pay the outstanding term loan facility.</li>    <li>For Q4, it's guiding to total revenue of $41.4M-$41.9M (vs. $41.5M consensus), with CPaaS revenue coming in at $34.2M-$34.7M. It sees non-GAAP EPS of $0.00-$0.01, above consensus for -$0.02.</li>    <li>For the full year, total revenues are forecast at $161.9M-$162.4M, above consensus for $161.5M. EPS is forecast at $0.50-$0.51, vs. consensus for $0.66.</li>    <li><a href=\"https://investors.bandwidth.com/\" target=\"_blank\">Conference call</a> to come at 5 p.m. ET.</li>    <li><a href=\"https://seekingalpha.com/pr/17026494-bandwidth-announces-third-quarter-2017-financial-results\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3318154\" data-linked=\"Bandwidth +10.2% as first public report shows revenue growth\" data-tweet=\"$BAND - Bandwidth +10.2% as first public report shows revenue growth https://seekingalpha.com/news/3318154-bandwidthplus-10_2-first-public-report-shows-revenue-growth?source=tweet\" data-url=\"https://seekingalpha.com/news/3318154-bandwidthplus-10_2-first-public-report-shows-revenue-growth\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:32 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318148\" data-ts=\"1513200336\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PIR\" target=\"_blank\">PIR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318148-soft-guidance-crushes-pier-1-imports\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Soft guidance crushes Pier 1 Imports</a></h4><ul> <li>Pier 1 Imports (NYSE:<a href='https://seekingalpha.com/symbol/PIR' title='Pier 1 Imports Inc.'>PIR</a>) reports comparable sales fell 0.7% in <a href=\"https://seekingalpha.com/pr/17026517-pier-1-imports-inc-reports-third-quarter-fiscal-2018-financial-results\" target=\"_blank\">FQ3</a>. The company says the hurricanes in Florida and Texas impacted comparable sales by about 100 bps.</li> <li>E-commerce penetration rose six full percentage points to 26% of sales during the quarter.</li> <li>The higher mix of e-commerce sales contributed to a drop in gross profit rate to 37.7% of sales vs. 41.3% a year ago. Merchandise margin fell to 57.3% of sales vs. 60.2% a year ago.</li> <li>Pier 1 ended the quarter with an inventory position of $419M, down 13% Y/Y.</li> <li>Q4 guidance: Comparable sales growth -3.5% to -1.5%, total sales growth +1% to +3%, EPS $0.16 to $0.24 vs. $0.38 consensus.</li> <li>Full-year guidance: Comparable sales growth -1% to flat, total sales growth is expected to be flat, EPS $0.17 to $0.25.</li> <li>Shares of Pier 1 are <font color='red'>down 21%</font> AH to $4.60.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3318148\" data-linked=\"Soft guidance crushes Pier 1 Imports\" data-tweet=\"$PIR - Soft guidance crushes Pier 1 Imports https://seekingalpha.com/news/3318148-soft-guidance-crushes-pier-1-imports?source=tweet\" data-url=\"https://seekingalpha.com/news/3318148-soft-guidance-crushes-pier-1-imports\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:25 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318124\" data-ts=\"1513198043\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SYNA\" target=\"_blank\">SYNA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318124-synapticsplus-5_6-after-upbeat-analyst-day-analyst-comments\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Synaptics +5.6% after &quot;upbeat&quot; analyst day, analyst comments</a></h4><ul><li>        Synaptics (NASDAQ:<a href='https://seekingalpha.com/symbol/SYNA' title='Synaptics Incorporated'>SYNA</a>) shares are&nbsp;<font color='green'>up 5.6%</font>&nbsp;after yesterday&rsquo;s analyst day was &ldquo;upbeat.&rdquo;</li><li>        Mizuho says Synaptics was optimistic about its acquisitions and IoT opportunities during the event. The company mentioned successes in its in-display fingerprint sensor.</li><li>                  Mizuho rates Synaptics at Neutral with a &nbsp;$42 price target.    </li><li>               Cowen raises its price target from $53 to $58 as Synaptics&rsquo; mid-term target has operating margins above the firm&rsquo;s expectations.&nbsp;</li><li>               Cowen calls Synaptics &ldquo;significantly undervalued&rdquo; and expects multiple OEM launches next year with higher ASPs than past products.&nbsp;</li><li>               Stifel notes that the company&rsquo;s total addressable market is now over $10.6B, up from $7.9B before the recent acquisitions.&nbsp;</li><li>               Source: Bloomberg First Word&nbsp; &nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3317846-synaptics-enters-mass-production-display-fingerprint-sensor\" target=\"_blank\">Synaptics enters mass production for in-display fingerprint sensor</a> (Dec. 12)</li></ul><div class=\"tiny-share-widget\" data-id=\"3318124\" data-linked=\"Synaptics +5.6% after &quot;upbeat&quot; analyst day, analyst comments\" data-tweet=\"$SYNA - Synaptics +5.6% after &quot;upbeat&quot; analyst day, analyst comments https://seekingalpha.com/news/3318124-synapticsplus-5_6-after-upbeat-analyst-day-analyst-comments?source=tweet\" data-url=\"https://seekingalpha.com/news/3318124-synapticsplus-5_6-after-upbeat-analyst-day-analyst-comments\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:47 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318122\" data-ts=\"1513197157\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMAT\" target=\"_blank\">AMAT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318122-stifel-names-top-wafer-fab-equipment-buys\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stifel names top wafer fab equipment buys</a></h4><ul><li>        Stifel <a href=\"http://www.briefing.com/DisplayArticle/ArticlePopup.aspx?ArticleId=IN20171213152124SMH\" target=\"_blank\">expects</a> wafer fab equipment spending to finish near $44B for 2017 and project 5% growth to $46B next year.</li><li>               The firm thinks the WFE industry has become more secular, dimming the relevance of cyclical trends.&nbsp;</li><li>               Stifel&rsquo;s top WFE picks (with rating and price target): Applied Materials (<a href='https://seekingalpha.com/symbol/AMAT' title='Applied Materials, Inc.'>AMAT</a> <font color='green'>+0.9%</font>), Buy and $50.47; MKS Instruments (<a href='https://seekingalpha.com/symbol/MKSI' title='MKS Instruments, Inc.'>MKSI</a> <font color='green'>+0.9%</font>), Buy and $93.15; Entegris (<a href='https://seekingalpha.com/symbol/ENTG' title='Entegris, Inc.'>ENTG</a> <font color='red'>-0.2%</font>), Buy and $29.55; FormFactor (<a href='https://seekingalpha.com/symbol/FORM' title='FormFactor, Inc.'>FORM</a> <font color='green'>+0.3%</font>), Buy and $14.85; Ichor Holdings (<a href='https://seekingalpha.com/symbol/ICHR' title='Ichor Holdings, Ltd.'>ICHR</a> <font color='green'>+0.7%</font>), Buy and $23.64. &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3317894-western-digital-toshiba-announce-agreement-chip-unit-fab-6\" target=\"_blank\">Western Digital and Toshiba announce agreement on chip unit, Fab 6</a> (Dec. 12)</li></ul><div class=\"tiny-share-widget\" data-id=\"3318122\" data-linked=\"Stifel names top wafer fab equipment buys\" data-tweet=\"$AMAT $AMAT $MKSI - Stifel names top wafer fab equipment buys https://seekingalpha.com/news/3318122-stifel-names-top-wafer-fab-equipment-buys?source=tweet\" data-url=\"https://seekingalpha.com/news/3318122-stifel-names-top-wafer-fab-equipment-buys\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:32 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318121\" data-ts=\"1513196995\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CMCSA\" target=\"_blank\">CMCSA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318121-tivo-drops-again-on-riley-patent-skepticism\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TiVo drops again on more Riley patent skepticism</a></h4><ul>   <li>With an eye to the company's patent dispute with Comcast (NASDAQ:<a href='https://seekingalpha.com/symbol/CMCSA' title='Comcast Corporation'>CMCSA</a>), B. Riley has cut TiVo (NASDAQ:<a href='https://seekingalpha.com/symbol/TIVO' title='TiVo Inc.'>TIVO</a>) to Neutral.</li>    <li>TiVo shares are <font color='red'>down 6.6%</font> today.</li>    <li>Shares slid last week when Riley <a href=\"https://seekingalpha.com/news/3316195-tivo-minus-6_8-percent-b-riley-sees-uncertainty-around-comcast-patent-ruling\" target=\"_blank\">maintained a Buy rating but trimmed its price target</a> on the same issue: uncertainty around the patent ruling.</li>    <li>Comcast has worked around the ITC ruling and that opens a door to \"potentially working to avoid an ongoing license,\" says Riley's Eric Wold. And TiVo's pursuit of other patents would be a multi-year process.</li>    <li>He had cut the price target to $24 from $31 last week; now he's cutting to a Street low of $18, vs. today's price of $14.85.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3318121\" data-linked=\"TiVo drops again on more Riley patent skepticism\" data-tweet=\"$CMCSA $CMCSA $TIVO - TiVo drops again on more Riley patent skepticism https://seekingalpha.com/news/3318121-tivo-drops-again-on-riley-patent-skepticism?source=tweet\" data-url=\"https://seekingalpha.com/news/3318121-tivo-drops-again-on-riley-patent-skepticism\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:29 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318119\" data-ts=\"1513196702\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AEMD\" target=\"_blank\">AEMD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318119-aethlon-medical-breaks-out-shares-up-38\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aethlon Medical breaks out, shares up 38%</a></h4><ul><li>Nano cap Aethlon Medical (<a href='https://seekingalpha.com/symbol/AEMD' title='Aethlon Medical, Inc.'>AEMD</a> <font color='green'>+37.5%</font>) breaks out of a two-month base on more than a 6x surge in volume. No particular news accounts for the action. Many times it presages an equity offering although the company just completed one two months ago.</li><li>In October, the company raised ~$6M via the sale of ~5.5M units at $1.10 per unit.</li><li>At end of September, the company had $920K in cash while operations consumed ~$1M in each of the two most recent quarters. Assuming the same rate of cash use, it will need to raise additional capital in late Q1/early Q2, if not earlier.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3298596-aethlon-medical-prices-equity-offering-shares-35-percent-premarket\" target=\"_blank\">Aethlon Medical prices equity offering; shares down 35% premarket</a> (Oct. 2)</li></ul><div class=\"tiny-share-widget\" data-id=\"3318119\" data-linked=\"Aethlon Medical breaks out, shares up 38%\" data-tweet=\"$AEMD - Aethlon Medical breaks out, shares up 38% https://seekingalpha.com/news/3318119-aethlon-medical-breaks-out-shares-up-38?source=tweet\" data-url=\"https://seekingalpha.com/news/3318119-aethlon-medical-breaks-out-shares-up-38\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:25 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318112\" data-ts=\"1513194986\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318112-technology-top-gainers-losers-of-2-55-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 2:55 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/CPAH' title='CounterPath Corporation'>CPAH</a> <font color='green'>+84%</font>. <a href='https://seekingalpha.com/symbol/DPW' title='DPW Holdings, Inc.'>DPW</a> <font color='green'>+24%</font>. <a href='https://seekingalpha.com/symbol/STRM' title='Streamline Health Solutions, Inc.'>STRM</a> <font color='green'>+24%</font>. <a href='https://seekingalpha.com/symbol/FNSR' title='Finisar Corporation'>FNSR</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/ELTK' title='Eltek Ltd.'>ELTK</a> <font color='green'>+19%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/HMNY' title='Helios and Matheson Analytics, Inc.'>HMNY</a> <font color='red'>-34%</font>. <a href='https://seekingalpha.com/symbol/BVSN' title='BroadVision, Inc.'>BVSN</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/OPNT' title='Opiant Pharmaceuticals, Inc.'>OPNT</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/NETE' title='Net Element International, Inc.'>NETE</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/RDFN' title='Redfin'>RDFN</a> <font color='red'>-9%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3318112\" data-linked=\"Technology - Top Gainers / Losers as of 2:55 pm\" data-tweet=\"$CPAH $DPW $STRM - Technology - Top Gainers / Losers as of 2:55 pm https://seekingalpha.com/news/3318112-technology-top-gainers-losers-of-2-55-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3318112-technology-top-gainers-losers-of-2-55-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:56 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318111\" data-ts=\"1513194779\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FFIV\" target=\"_blank\">FFIV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318111-another-exec-departing-f5-cfo-sets-retirement\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Another exec departing F5 as CFO sets retirement</a></h4><ul>   <li>F5 Networks (<a href=\"http://seekingalpha.com/symbol/FFIV\" target=\"_blank\">FFIV</a> <font color='red'>-2.9%</font>) says its chief financial officer <a href=\"https://www.sec.gov/Archives/edgar/data/1048695/000104869517000032/ffiv8-k12122017.htm\" target=\"_blank\">informed the company he's retiring</a> in F5's fiscal third quarter.</li>    <li>That quarter ends June 30, 2018; Andrew Reinland will stay in the role until then.</li>    <li>That follows the retirement last month of its chief operating officer Edward Eames, and news early this month of the resignation of chief marketing officer Benjamin Gibson to pursue another opportunity.</li>    <li>And CEO Francois Locoh-Donou joined in April after the retirement of John McAdam.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3318111\" data-linked=\"Another exec departing F5 as CFO sets retirement\" data-tweet=\"$FFIV - Another exec departing F5 as CFO sets retirement https://seekingalpha.com/news/3318111-another-exec-departing-f5-cfo-sets-retirement?source=tweet\" data-url=\"https://seekingalpha.com/news/3318111-another-exec-departing-f5-cfo-sets-retirement\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:52 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318109\" data-ts=\"1513193804\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GRUB\" target=\"_blank\">GRUB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318109-grubhub-in-nationwide-deal-cheesecake-factory\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GrubHub in nationwide deal with Cheesecake Factory</a></h4><ul>   <li>GrubHub (<a href=\"http://seekingalpha.com/symbol/GRUB\" target=\"_blank\">GRUB</a> <font color='green'>+1.8%</font>) has <a href=\"https://seekingalpha.com/pr/17026105-grubhub-expands-partnership-cheesecake-factory-deliver-menu-favorites-coast-coast\" target=\"_blank\">expanded its deal with The Cheesecake Factory</a> nationwide.</li>    <li>The food-ordering and delivery service will offer Cheesecake Factory items in 18 states.</li>    <li>That means home delivery in Alabama, Arizona, California, Connecticut, Florida, Kentucky, Michigan, Nebraska, New Jersey, New Mexico, New York, Oregon, Pennsylvania, Rhode Island, Tennessee, Utah, Virginia, and Wisconsin.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3318109\" data-linked=\"GrubHub in nationwide deal with Cheesecake Factory\" data-tweet=\"$GRUB - GrubHub in nationwide deal with Cheesecake Factory https://seekingalpha.com/news/3318109-grubhub-in-nationwide-deal-cheesecake-factory?source=tweet\" data-url=\"https://seekingalpha.com/news/3318109-grubhub-in-nationwide-deal-cheesecake-factory\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318107\" data-ts=\"1513193299\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FNSR\" target=\"_blank\">FNSR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318107-finisar-clarifies-apple-investment-apple-coo-discusses-1b-funds-limits\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Finisar clarifies Apple investment, Apple COO discusses $1B fund&#39;s limits</a></h4><ul><li>Finisar (NASDAQ:<a href='https://seekingalpha.com/symbol/FNSR' title='Finisar Corporation'>FNSR</a>) <a href=\"https://www.sec.gov/Archives/edgar/data/1094739/000110465917073092/a17-28415_18k.htm\" target=\"_blank\">releases</a> a statement clarifying the $390M Apple (NASDAQ:<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a>) investment announced this morning.</li><li>&rdquo;Apple has not made a debt or equity investment in Finisar. The amount referred to by Apple represents anticipated future business between the companies over a period of time.&rdquo;</li><li>The Finisar funding was the second project from Apple&rsquo;s $1B Advanced Manufacturing Fund, which previously invested $200M in Corning.</li><li>Apple COO Jeff Williams <a href=\"https://www.cnbc.com/2017/12/13/apple-coo-jeff-williams-we-could-invest-more-than-1-billion-in-us.html\" target=\"_blank\">tells CNBC</a> that $1B isn&rsquo;t the upper limit of the fund. Williams says the company isn&rsquo;t &ldquo;thinking in terms of a fund limit&rdquo; but rather &ldquo;where are the opportunities across the U.S. to help nurture companies that are making the advanced technology.&rdquo;</li><li>Finisar shares are&nbsp;<font color='green'>up 22%</font>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3317967-apple-invests-390m-finisar\" target=\"_blank\">Apple invests $390M in Finisar</a> (Dec. 13)</li></ul><div class=\"tiny-share-widget\" data-id=\"3318107\" data-linked=\"Finisar clarifies Apple investment, Apple COO discusses $1B fund&#39;s limits\" data-tweet=\"$FNSR $FNSR $AAPL - Finisar clarifies Apple investment, Apple COO discusses $1B fund&#39;s limits https://seekingalpha.com/news/3318107-finisar-clarifies-apple-investment-apple-coo-discusses-1b-funds-limits?source=tweet\" data-url=\"https://seekingalpha.com/news/3318107-finisar-clarifies-apple-investment-apple-coo-discusses-1b-funds-limits\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:28 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318106\" data-ts=\"1513192712\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318106-treasurys-hold-gains-after-fed-gold-gains\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Treasurys hold gains after Fed, gold gains</a></h4><ul><li>Things out of the Fed this afternoon sound somewhat hawkish - the central bank hiking rates 25 basis points, holding fast to its expectations for three more moves in 2018, and a sizable increase in its estimate for GDP growth next year (alongside a decent drop in the expected unemployment rate).</li><li>Outgoing Chair Janet Yellen, however, was not able to keep the doves in line, with the Chicago Fed's Evans and the Minneapolis Fed's Kashkari both dissenting from today's vote to raise rates.</li><li>Next year, though, will see both of those doves rotating out of voting membership on the FOMC. Among those getting votes will be hawks at the San Francisco and Cleveland Feds.</li><li>The 10-year Treasury yield remains down about four basis points. <a href='https://seekingalpha.com/symbol/TLT' title='iShares 20+ Year Treasury Bond ETF'>TLT</a>&nbsp;<font color='green'>+0.6%</font>, <a href='https://seekingalpha.com/symbol/TBT' title='ProShares UltraShort 20+ Year Treasury ETF'>TBT</a><font color='red'> -1.2%</font></li><li>Gold (NYSEARCA:<a href='https://seekingalpha.com/symbol/GLD' title='SPDR Gold Trust ETF'>GLD</a>) has added a bit to gains, now up 0.8%, while the dollar (NYSEARCA:<a href='https://seekingalpha.com/symbol/UUP' title='PowerShares DB USD Bull ETF'>UUP</a>) remains just modestly lower.</li><li>Janet Yellen's <a href=\"https://www.federalreserve.gov/live-broadcast.htm\" target=\"_blank\">press conference</a> begins at 2:30 ET.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3318105-fed-still-sees-three-rate-hikes-next-year\" target=\"_blank\">Fed still sees three rate hikes next year</a> (Dec. 13)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3318103-fed-hikes-rates-third-time-year\" target=\"_blank\">Fed hikes rates for third time this year</a> (Dec. 13)</li></ul><div class=\"tiny-share-widget\" data-id=\"3318106\" data-linked=\"Treasurys hold gains after Fed, gold gains\" data-tweet=\"$TLT $TBT $GLD - Treasurys hold gains after Fed, gold gains https://seekingalpha.com/news/3318106-treasurys-hold-gains-after-fed-gold-gains?source=tweet\" data-url=\"https://seekingalpha.com/news/3318106-treasurys-hold-gains-after-fed-gold-gains\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:18 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>24&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318104\" data-ts=\"1513191740\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318104-energy-materials-top-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/SVM' title='Silvercorp Metals Inc.'>SVM</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/AG' title='First Majestic Silver Corp.'>AG</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/EXK' title='Endeavour Silver Corp.'>EXK</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/MUX' title='McEwen Mining Inc.'>MUX</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/NDRO-OLD' title='Enduro Royalty Trust'>NDRO-OLD</a> <font color='green'>+7%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/BRS' title='Bristow Group Inc.'>BRS</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/REXX' title='Rex Energy Corporation'>REXX</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/WLB' title='Westmoreland Coal Co'>WLB</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/NBLX' title='Noble Midstream Partners LP'>NBLX</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/TRCH' title='Torchlight Energy Resources, Inc.'>TRCH</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3318104\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm\" data-tweet=\"$SVM $AG $EXK - Energy/Materials - Top Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3318104-energy-materials-top-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3318104-energy-materials-top-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:02 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318098\" data-ts=\"1513190358\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EADSY\" target=\"_blank\">EADSY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318098-airbus-beats-out-boeing-for-big-delta-order-cnn\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Airbus beats out Boeing for big Delta order - CNN</a></h4><ul><li><a href=\"http://ht.ly/giId50fHjly\" target=\"_blank\">According to the report</a>, Delta later today will announce a deal for about 100 Airbus (<a href='https://seekingalpha.com/symbol/EADSY' title='Airbus SE ADR'>OTCPK:EADSY</a> <font color='red'>-0.1%</font>) A321neo jets. Alongside will be a purchase of Pratt &amp; Whitney (<a href='https://seekingalpha.com/symbol/UTX' title='United Technologies Corporation'>UTX</a> <font color='green'>+0.6%</font>) engines.</li><li>Boeing (NYSE:<a href='https://seekingalpha.com/symbol/BA' title='The Boeing Company'>BA</a>) had hoped the order would be for its 737 Max 10s.</li><li>This would come one day after Canada <a href=\"https://seekingalpha.com/news/3317836-canada-scraps-boeing-deal-talks-tough-upcoming-contract-88-jets\" target=\"_blank\">officially scrapped</a> plans for 18 new Super Hornets in favor of used fighters from Australia.</li></ul><div class=\"tiny-share-widget\" data-id=\"3318098\" data-linked=\"Airbus beats out Boeing for big Delta order - CNN\" data-tweet=\"$EADSY $EADSY $UTX - Airbus beats out Boeing for big Delta order - CNN https://seekingalpha.com/news/3318098-airbus-beats-out-boeing-for-big-delta-order-cnn?source=tweet\" data-url=\"https://seekingalpha.com/news/3318098-airbus-beats-out-boeing-for-big-delta-order-cnn\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:39 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>81&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318097\" data-ts=\"1513190133\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ICPT\" target=\"_blank\">ICPT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318097-longs-quietly-moving-intercept-pharma-shares-up-9\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Longs quietly moving into Intercept Pharma; shares up 9%</a></h4><ul><li>Intercept Pharmaceuticals (<a href='https://seekingalpha.com/symbol/ICPT' title='Intercept Pharmaceuticals'>ICPT</a> <font color='green'>+8.9%</font>) is approaching near-term resistance as investors move into the stock after September's plunge. Shares lost about half their value after the company reported patient deaths due to incorrect dosing of Ocaliva (obeticholic acid) in patients with primary biliary cholangitis &#40;PBC&#41;.</li><li>Deutsche Bank upgraded the stock to Strong Buy this morning. According to Yahoo Finance, 10 of 20 analysts are bullish on the stock.</li><li>In October, the company reported positive results in a Phase 2 study of Ocaliva in primary sclerosing cholangitis, a potential new use for the product. The FDA approved it in May 2016 for PBC.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3297274-intercept-reports-ocaliva-related-deaths-certain-pbc-patients-due-failure-follow-recommended\" target=\"_blank\">Intercept reports that Ocaliva-related deaths in certain PBC patients due to failure to follow recommended dosing regimen; shares ahead 5% premarket</a> (Sept. 25)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3303090-intercepts-oca-shows-treatment-effect-mid-stage-psc-study-shares-ahead-3-percent-hours\" target=\"_blank\">Intercept's OCA shows treatment effect in mid-stage PSC study; shares ahead 3% after hours</a> (Oct. 23)</li></ul><div class=\"tiny-share-widget\" data-id=\"3318097\" data-linked=\"Longs quietly moving into Intercept Pharma; shares up 9%\" data-tweet=\"$ICPT - Longs quietly moving into Intercept Pharma; shares up 9% https://seekingalpha.com/news/3318097-longs-quietly-moving-intercept-pharma-shares-up-9?source=tweet\" data-url=\"https://seekingalpha.com/news/3318097-longs-quietly-moving-intercept-pharma-shares-up-9\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318093\" data-ts=\"1513188379\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MTN\" target=\"_blank\">MTN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318093-vail-resorts-rides-deutsche-bank-upgrade-higher\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vail Resorts rides Deutsche Bank upgrade higher</a></h4><ul> <li>Vail Resorts (<a href='https://seekingalpha.com/symbol/MTN' title='Vail Resorts, Inc.'>MTN</a> <font color='green'>+1.2%</font>) tracks higher after Deutsche Bank initiates <a href=\"https://twitter.com/RatingsNetwork/status/940921937865400320\" target=\"_blank\">coverage</a> on the resort operator with a Buy rating.</li> <li>Deutsche Bank's price target of $265 on Vail reps +20% upside potential.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3318093\" data-linked=\"Vail Resorts rides Deutsche Bank upgrade higher\" data-tweet=\"$MTN - Vail Resorts rides Deutsche Bank upgrade higher https://seekingalpha.com/news/3318093-vail-resorts-rides-deutsche-bank-upgrade-higher?source=tweet\" data-url=\"https://seekingalpha.com/news/3318093-vail-resorts-rides-deutsche-bank-upgrade-higher\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:06 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318090\" data-ts=\"1513187191\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318090-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/CPAH' title='CounterPath Corporation'>CPAH</a> <font color='green'>+100%</font>. <a href='https://seekingalpha.com/symbol/ELTK' title='Eltek Ltd.'>ELTK</a> <font color='green'>+38%</font>. <a href='https://seekingalpha.com/symbol/DPW' title='DPW Holdings, Inc.'>DPW</a> <font color='green'>+29%</font>. <a href='https://seekingalpha.com/symbol/STRM' title='Streamline Health Solutions, Inc.'>STRM</a> <font color='green'>+28%</font>. <a href='https://seekingalpha.com/symbol/FNSR' title='Finisar Corporation'>FNSR</a> <font color='green'>+28%</font>. <a href='https://seekingalpha.com/symbol/VERU' title='Veru Inc.'>VERU</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/SMSI' title='Smith Micro Software, Inc.'>SMSI</a> <font color='green'>+19%</font>. LTEA <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/MFIN' title='Medallion Financial'>MFIN</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/CLLS' title='Cellectis S.A.'>CLLS</a> <font color='green'>+14%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/HMNY' title='Helios and Matheson Analytics, Inc.'>HMNY</a> <font color='red'>-32%</font>. <a href='https://seekingalpha.com/symbol/NAT' title='Nordic American Tankers Limited'>NAT</a> <font color='red'>-25%</font>. <a href='https://seekingalpha.com/symbol/BRS' title='Bristow Group Inc.'>BRS</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/RIOT' title='Riot Blockchain, Inc.'>RIOT</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/LENS' title='Presbia'>LENS</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/CIVI' title='Civitas Solutions'>CIVI</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/CHCI' title='Comstock Homebuilding Companies, Inc.'>CHCI</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/TIK' title='Tel-Instrument Electronics Corp'>TIK</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/BVSN' title='BroadVision, Inc.'>BVSN</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/ARCB' title='ArcBest Corporation'>ARCB</a>&nbsp;<font color='red'>-10%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3318090\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$CPAH $ELTK $DPW - Midday Gainers / Losers https://seekingalpha.com/news/3318090-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3318090-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:46 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318088\" data-ts=\"1513187044\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEVA\" target=\"_blank\">TEVA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318088-teva-down-6-ahead-of-details-on-restructuring-plan\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Teva down 6% ahead of details on restructuring plan</a></h4><ul><li>Teva Pharmaceutical Industries (<a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a> <font color='red'>-5.8%</font>) slumps on average volume ahead of tomorrow's <a href=\"https://seekingalpha.com/pr/17026244-teva-host-conference-call-discuss-restructuring-plan-additional-measures-improve-business\" target=\"_blank\">press release</a> at 7:00 am ET detailing its restructuring plan. A conference call will follow an hour later.</li><li>According to an earlier report, the plan includes laying off 1/3 of its Israel-based workforce.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3317935-teva-restructuring-plan-coming-thursday\" target=\"_blank\">Teva restructuring plan coming Thursday</a> (Dec. 13)</li></ul><div class=\"tiny-share-widget\" data-id=\"3318088\" data-linked=\"Teva down 6% ahead of details on restructuring plan\" data-tweet=\"$TEVA - Teva down 6% ahead of details on restructuring plan https://seekingalpha.com/news/3318088-teva-down-6-ahead-of-details-on-restructuring-plan?source=tweet\" data-url=\"https://seekingalpha.com/news/3318088-teva-down-6-ahead-of-details-on-restructuring-plan\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:44 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>72&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318087\" data-ts=\"1513186482\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AYI\" target=\"_blank\">AYI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318087-acuity-brands-drops-6_5-on-baird-lighting-survey\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Acuity Brands drops 6.5% on Baird Lighting Survey</a></h4><ul><li>        Acuity Brands (NYSE:<a href='https://seekingalpha.com/symbol/AYI' title='Acuity Brands, Inc. &#40;Holding Company&#41;'>AYI</a>) falls after a Baird analyst says lighting volume in Q1 looks flat on the year.</li><li>                  Analyst Timothy Wojs cites a survey that shows lighting volume slowing from the 3% gains last quarter and pricing that will remain challenging partly due to imports.&nbsp;    </li><li>               Baird rates Acuity at Neutral with a $178 price target, down from $186.&nbsp;</li><li>                  Source: Bloomberg First Word    </li><li>                  Acuity Brands shares are&nbsp;<font color='red'>down 6.5%</font>.&nbsp; </li></ul><div class=\"tiny-share-widget\" data-id=\"3318087\" data-linked=\"Acuity Brands drops 6.5% on Baird Lighting Survey\" data-tweet=\"$AYI - Acuity Brands drops 6.5% on Baird Lighting Survey https://seekingalpha.com/news/3318087-acuity-brands-drops-6_5-on-baird-lighting-survey?source=tweet\" data-url=\"https://seekingalpha.com/news/3318087-acuity-brands-drops-6_5-on-baird-lighting-survey\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:34 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318084\" data-ts=\"1513186093\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CNHI\" target=\"_blank\">CNHI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318084-caterpillars-big-run-continues-barclays-positive-goldman-lifts-pt\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Caterpillar&#39;s big run continues; Barclays positive, Goldman lifts PT</a></h4><ul><li>Initiating coverage on the U.S. machinery and construction sector, Barclays' Adam Seiden, says sales bases are low, political rhetoric high, and risk/reward skewed positive even after a big run this year.</li><li>His top pick is CNH Industrial (<a href='https://seekingalpha.com/symbol/CNHI' title='CNH Industrial N.V.'>CNHI</a> <font color='green'>+2.1%</font>), but he's also overweight Caterpillar (<a href='https://seekingalpha.com/symbol/CAT' title='Caterpillar Inc.'>CAT</a> <font color='green'>+3.3%</font>), Deere (<a href='https://seekingalpha.com/symbol/DE' title='Deere & Company'>DE</a> <font color='green'>+1.2%</font>), Herc Holdings (<a href='https://seekingalpha.com/symbol/HRI' title='Herc Holdings'>HRI</a> <font color='green'>+2.2%</font>), Jacobs Engineering (<a href='https://seekingalpha.com/symbol/JEC' title='Jacobs Engineering Group Inc.'>JEC</a> <font color='green'>+0.9%</font>), Manitowoc (<a href='https://seekingalpha.com/symbol/MTW' title='Manitowoc Company, Inc.'>MTW</a> <font color='green'>+1.8%</font>), Vulcan Material (<a href='https://seekingalpha.com/symbol/VMC' title='Vulcan Materials Company'>VMC</a> <font color='green'>+0.9%</font>), and Welbilt (<a href='https://seekingalpha.com/symbol/WBT' title='Welbilt, Inc.'>WBT</a> <font color='green'>+0.6%</font>). He's underweight Aecom (<a href='https://seekingalpha.com/symbol/ACM' title='AECOM Technology Corporation'>ACM</a> <font color='red'>-2.1%</font>), and United Rentals (<a href='https://seekingalpha.com/symbol/URI' title='United Rentals, Inc.'>URI</a> <font color='green'>+0.7%</font>).</li><li>Meanwhile, Bloomberg reports Goldman as having boosted its already Street-high earnings estimates for CAT.</li><li>CAT earlier today reported retail machine sales as up 26% in November vs. 19% in October and 13% in September.</li><li>The industrials' (<a href='https://seekingalpha.com/symbol/XLI' title='Industrial Select Sector SPDR ETF'>XLI</a> <font color='green'>+0.7%</font>) gain today is easily besting the S&amp;P 500's&nbsp;<font color='green'>0.2% advance</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3318084\" data-linked=\"Caterpillar&#39;s big run continues; Barclays positive, Goldman lifts PT\" data-tweet=\"$CNHI $CNHI $CAT - Caterpillar&#39;s big run continues; Barclays positive, Goldman lifts PT https://seekingalpha.com/news/3318084-caterpillars-big-run-continues-barclays-positive-goldman-lifts-pt?source=tweet\" data-url=\"https://seekingalpha.com/news/3318084-caterpillars-big-run-continues-barclays-positive-goldman-lifts-pt\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:28 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318083\" data-ts=\"1513185801\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CERN\" target=\"_blank\">CERN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318083-cerner-slips-1-on-delay-in-va-ehr-contract\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cerner slips 1% on delay in VA EHR contract</a></h4><ul><li>Cerner (<a href='https://seekingalpha.com/symbol/CERN' title='Cerner Corporation'>CERN</a> <font color='red'>-0.8%</font>) eases on light volume in apparent response to the <a href=\"https://www.politico.com/story/2017/12/13/shulkin-cerner-contract-held-up-by-interoperability-questions-294971\" target=\"_blank\">news </a>that the Department of Veterans Affairs is holding up its electronic health record &#40;EHR&#41; contract due to questions about its interoperability with private sector partners.</li><li>VA Secretary David Shulkin acknowledges that the industry has struggled with the problem due to proprietary systems of vendors which may be unfair to big players (like Cerner). He says his agency has issued a request for information seeking data-sharing solutions in addition to ways to test interoperability.</li><li>Cerner's contract is valued at $10B or more.</li></ul><div class=\"tiny-share-widget\" data-id=\"3318083\" data-linked=\"Cerner slips 1% on delay in VA EHR contract\" data-tweet=\"$CERN - Cerner slips 1% on delay in VA EHR contract https://seekingalpha.com/news/3318083-cerner-slips-1-on-delay-in-va-ehr-contract?source=tweet\" data-url=\"https://seekingalpha.com/news/3318083-cerner-slips-1-on-delay-in-va-ehr-contract\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:23 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318082\" data-ts=\"1513184867\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MBVX\" target=\"_blank\">MBVX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318082-mabvax-completes-enrollment-in-first-cohort-in-early-stage-study-of-cancer-candidate-mvtminus\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MabVax completes enrollment in first cohort in early-stage study of cancer candidate MVT-1075; shares up 4%</a></h4><ul><li>MabVax Therapeutics Holdings (<a href='https://seekingalpha.com/symbol/MBVX' title='MABVAX THERAPEUTICS HLDGS'>OTCPK:MBVX</a> <font color='green'>+3.8%</font>) completes enrollment in the first cohort of a 22-subject Phase 1 study assessing human antibody-based radioimmunotherapy candidate MVT-1075 in patients with metastatic CA19-9-positive pancreatic, colon and lung cancers.</li><li>The primary objective of the open-label study is safety and to determine the maximum tolerated dose. Secondary endpoints include efficacy measures.</li><li>Interim data should be available early next quarter.</li><li>MVT-1075 is a targeted cancer therapy that utilizes a fully human monoclonal antibody, HuMab-5B1, to deliver a cytotoxic payload, the radioisotope <a href=\"https://atlasofscience.org/lutetium-177-radioisotope-targeted-therapy-for-treatment-of-cancer-and-other-diseases/\" target=\"_blank\">Lutetium-177</a>, to cancer cells expressing the <a href=\"https://en.wikipedia.org/wiki/CA19-9\" target=\"_blank\">CA19-9 protein</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3318082\" data-linked=\"MabVax completes enrollment in first cohort in early-stage study of cancer candidate MVT-1075; shares up 4%\" data-tweet=\"$MBVX $MBVXQ - MabVax completes enrollment in first cohort in early-stage study of cancer candidate MVT-1075; shares up 4% https://seekingalpha.com/news/3318082-mabvax-completes-enrollment-in-first-cohort-in-early-stage-study-of-cancer-candidate-mvtminus?source=tweet\" data-url=\"https://seekingalpha.com/news/3318082-mabvax-completes-enrollment-in-first-cohort-in-early-stage-study-of-cancer-candidate-mvtminus\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:07 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318080\" data-ts=\"1513184482\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318080-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> LTEA <font color='green'>+23%</font>. <a href='https://seekingalpha.com/symbol/FUV' title='Arcimoto, Inc.'>FUV</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/BETR' title='Amplify Snack Brands'>BETR</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/WPRT' title='Westport Fuel Systems, Inc.'>WPRT</a> <font color='green'>+9%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3318080\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$LBCC $FUV $BETR-OLD - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3318080-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3318080-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318077\" data-ts=\"1513183586\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/STML\" target=\"_blank\">STML</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318077-stemlines-lead-candidate-successful-in-mid-stage-study-in-rare-bone-marrow-disorder-shares-up\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stemline&#39;s lead candidate successful in mid-stage study in rare bone marrow disorder; shares up 2%</a></h4><ul><li>Thinly traded micro cap Stemline Therapeutics (<a href='https://seekingalpha.com/symbol/STML' title='Stemline Therapeutics'>STML</a> <font color='green'>+2.3%</font>) is up, albeit on light volume, on the heels of its <a href=\"https://seekingalpha.com/pr/17025826-stemline-therapeutics-presents-detailed-slminus-401-pivotal-data-bpdcn-ash-kicks-bpdcn\" target=\"_blank\">announcement </a>of a successful outcome in a <a href=\"https://clinicaltrials.gov/ct2/show/NCT02113982?term=sl-401&amp;rank=5\" target=\"_blank\">Phase 2 clinical trial</a> assessing lead candidate SL-401 in patients with a rare bone marrow disorder called blastic plasmacytoid dendritic cell neoplasm &#40;DPDCN&#41;. The results were first reported in October.</li><li>Data from the pivotal Stage 3 portion of the trial showed an overall response rate &#40;ORR&#41; of 77% (n=10/13) and a 54% (n=7/13) complete response rate.</li><li>The company says it is preparing a U.S. marketing application.</li><li>Breakthrough Therapy- and Orphan Drug-tagged&nbsp;<a href=\"http://www.bloodjournal.org/content/124/3/385\" target=\"_blank\">SL-401</a>&nbsp;is a recombinant fusion protein composed of certain domains of the diptheria toxin fused to interleukin 3 (IL3). It is called a targeted therapy because the IL3 seeks out IL3 receptors on cancer stem cells (CSCs), the malignant \"seeds\" of tumors, and tumor bulk of blood cancers. Binding to the receptors delivers the cytotoxin directly to the cancer cells.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3306069-stemlines-slminus-401-successful-mid-stage-bpdcn-study-shares-ahead-8-percent-premarket\" target=\"_blank\">Stemline's SL-401 successful in mid-stage BPDCN study; shares ahead 8% premarket</a> (Oct. 31)</li></ul><div class=\"tiny-share-widget\" data-id=\"3318077\" data-linked=\"Stemline&#39;s lead candidate successful in mid-stage study in rare bone marrow disorder; shares up 2%\" data-tweet=\"$STML - Stemline&#39;s lead candidate successful in mid-stage study in rare bone marrow disorder; shares up 2% https://seekingalpha.com/news/3318077-stemlines-lead-candidate-successful-in-mid-stage-study-in-rare-bone-marrow-disorder-shares-up?source=tweet\" data-url=\"https://seekingalpha.com/news/3318077-stemlines-lead-candidate-successful-in-mid-stage-study-in-rare-bone-marrow-disorder-shares-up\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:46 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318071\" data-ts=\"1513181964\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INVVY\" target=\"_blank\">INVVY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318071-fda-accepts-indiviors-marketing-application-for-monthly-treatment-for-schizophrenia-licensor\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA accepts Indivior&#39;s marketing application for once-monthly treatment for schizophrenia; licensor DURECT up 1%</a></h4><ul><li>The FDA <a href=\"https://seekingalpha.com/pr/17025675-durect-announces-nda-acceptance-indiviors-rbpminus-7000-risperidone-monthly-depot\" target=\"_blank\">accepts for review</a> Indivior PLC's (<a href='https://seekingalpha.com/symbol/INVVY' title='INDIVIOR PLC ADR'>OTCPK:INVVY</a>) New Drug Application &#40;NDA&#41; seeking approval for RBP-7000 (risperidone), a once-monthly injection for the treatment of schizophrenia. The agency's action date is July 28, 2018.</li><li>Indivior acquired the U.S. rights from DURECT (<a href='https://seekingalpha.com/symbol/DRRX' title='Durect Corporation'>DRRX</a> <font color='green'>+0.8%</font>) in September 2017. Under the terms of the <a href=\"https://www.prnewswire.com/news-releases/durect-and-indivior-plc-sign-a-175-million-patent-purchase-agreement-300528619.html\" target=\"_blank\">agreement</a>, DURECT received $12.5M upfront and is eligible for a $5M regulatory milestone and quarterly earn-out payments based on a single-digit percentage of sales.</li></ul><div class=\"tiny-share-widget\" data-id=\"3318071\" data-linked=\"FDA accepts Indivior&#39;s marketing application for once-monthly treatment for schizophrenia; licensor DURECT up 1%\" data-tweet=\"$INVVY $INVVY $DRRX - FDA accepts Indivior&#39;s marketing application for once-monthly treatment for schizophrenia; licensor DURECT up 1% https://seekingalpha.com/news/3318071-fda-accepts-indiviors-marketing-application-for-monthly-treatment-for-schizophrenia-licensor?source=tweet\" data-url=\"https://seekingalpha.com/news/3318071-fda-accepts-indiviors-marketing-application-for-monthly-treatment-for-schizophrenia-licensor\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:19 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318070\" data-ts=\"1513181855\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TGT\" target=\"_blank\">TGT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318070-target-strikes-huge-day-grocery-delivery-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Target strikes huge same-day grocery delivery deal</a></h4><ul>     <li>Target (<a href='https://seekingalpha.com/symbol/TGT' title='Target Corporation'>TGT</a> <font color='green'>+1.5%</font>) signs a deal to acquire same-day grocery delivery specialist&nbsp;Shipt for $550M.</li>     <li>The retailer says it&nbsp;will leverage its network of stores and Shipt's proprietary technology platform and community of shoppers to quickly add same-day delivery.</li>     <li>The acquisition is expected to \"significantly accelerate\" Target's digital fulfillment efforts, including bringing same-day delivery services to customers at approximately half of Target stores by early 2018.</li>          <li>Source: <a href=\"https://seekingalpha.com/pr/17026209-target-acquire-day-delivery-platform-shipt-inc-bolster-fulfillment-capabilities\" target=\"_blank\">Press Release</a></li>      </ul><div class=\"tiny-share-widget\" data-id=\"3318070\" data-linked=\"Target strikes huge same-day grocery delivery deal\" data-tweet=\"$TGT - Target strikes huge same-day grocery delivery deal https://seekingalpha.com/news/3318070-target-strikes-huge-day-grocery-delivery-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3318070-target-strikes-huge-day-grocery-delivery-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>51&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318068\" data-ts=\"1513181326\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CMTL\" target=\"_blank\">CMTL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318068-comtechplus-5_6-on-order-news\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Comtech +5.6% on order news</a></h4><ul><li>        Comtech Telecommunications (NASDAQ:<a href='https://seekingalpha.com/symbol/CMTL' title='Comtech Telecommunications Corp.'>CMTL</a>) <a href=\"https://seekingalpha.com/pr/17026108-comtech-telecommunications-corp-receives-9_4-million-order-solid-state-power-amplifiers\" target=\"_blank\">received an order</a> for over $9.4M for solid-state power amplifiers (SSPAs) for in-flight connectivity applications.</li><li>               The order occurred in Q2 and will support Comtech Xicom Technology&rsquo;s continued production of the product until late 2018.</li><li>               Comtech shares are&nbsp;<font color='green'>up 5.6%.</font>&nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3318068\" data-linked=\"Comtech +5.6% on order news\" data-tweet=\"$CMTL - Comtech +5.6% on order news https://seekingalpha.com/news/3318068-comtechplus-5_6-on-order-news?source=tweet\" data-url=\"https://seekingalpha.com/news/3318068-comtechplus-5_6-on-order-news\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:08 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318067\" data-ts=\"1513181236\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CRCW\" target=\"_blank\">CRCW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318067-bitcoin-mania-seen-in-stock\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bitcoin mania as seen in a stock</a></h4><ul><li><a href=\"https://www.wsj.com/articles/bitcoin-mania-comes-to-the-stock-market-1513177024\" target=\"_blank\">via Charley Grant at the <em>WSJ</em></a></li><li>\"If I can quote Elon Musk,\" Crypto Co. (<a href='https://seekingalpha.com/symbol/CRCW' title='The Crypto Company'>OTC:CRCW</a>) CEO Michael Poutre tells the WSJ, \"we are working very hard to grow into our valuation.\"</li><li>Indeed. Prior to a massive tumble yesterday <a href=\"https://www.streetinsider.com/SEC+Filings/Form+8-K+Crypto+Co+For%3A+Dec+12/13596497.html\" target=\"_blank\">amid a sale of </a>1.15M shares, CRCW was up several thousand percent since September and had a $12B valuation.</li><li>And what of the current valuation of $4B? Investors get a company that says it develops&nbsp;proprietary technology, consults on blockchain and crypto assets, has $2.6 of cash, and $900K worth of cryptocurrency (though this could be well higher after the recent run). Total Q3 revenues were $488K - nearly all of that coming from realized trading profits.</li><li>The OTC Markets Group last week designated CRCW as a \"caveat emptor\" security.</li><li>Shares have yet to trade today.</li></ul><div class=\"tiny-share-widget\" data-id=\"3318067\" data-linked=\"Bitcoin mania as seen in a stock\" data-tweet=\"$CRCW - Bitcoin mania as seen in a stock https://seekingalpha.com/news/3318067-bitcoin-mania-seen-in-stock?source=tweet\" data-url=\"https://seekingalpha.com/news/3318067-bitcoin-mania-seen-in-stock\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:07 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318040\" data-ts=\"1513180878\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318040-healthcare-top-5-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/VERU' title='Veru Inc.'>VERU</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/CLLS' title='Cellectis S.A.'>CLLS</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/ENTA' title='Enanta Pharmaceuticals, Inc.'>ENTA</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/MNOV' title='MediciNova, Inc.'>MNOV</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/CAPR' title='Capricor Therapeutics, Inc.'>CAPR</a> <font color='green'>+8%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/LENS' title='Presbia'>LENS</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/RIOT' title='Riot Blockchain, Inc.'>RIOT</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/CIVI' title='Civitas Solutions'>CIVI</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/EYES' title='Second Sight Medical Products'>EYES</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/GHDX' title='Genomic Health, Inc.'>GHDX</a> <font color='red'>-8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3318040\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am\" data-tweet=\"$VERU $CLLS $ENTA - Healthcare - Top 5 Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3318040-healthcare-top-5-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3318040-healthcare-top-5-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:01 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318060\" data-ts=\"1513179762\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LXRX\" target=\"_blank\">LXRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318060-sanofis-planned-marketing-application-for-diabetes-med-propels-licensor-lexicon\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sanofi&#39;s planned marketing application for diabetes med propels licensor Lexicon Pharmaceuticals, up 4%</a></h4><ul><li>Lexicon Pharmaceuticals (<a href='https://seekingalpha.com/symbol/LXRX' title='Lexicon Pharmaceuticals, Inc.'>LXRX</a> <font color='green'>+4.3%</font>) perks up, albeit on light volume, in response to Sanofi's announcement that it plans on filing a U.S. marketing application for sotagliflozin in type 1 diabetes (T1D) in 2018.</li><li>Sanofi acquired exclusive global rights (except Japan) to the dual SGLT1 and SGLT2 inhibitor under a November 2015 agreement with Lexicon. Under the terms of the deal, Lexicon has co-promotion rights in the U.S. for T1D.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3317996-sanofi-expects-file-nine-regulatory-submissions-next-18-months\" target=\"_blank\">Sanofi expects to file nine regulatory submissions over next 18 months</a> (Dec. 13)</li><li>Previously: <a href=\"https://seekingalpha.com/news/2907056-sanofi-lexicon-pharma-sign-1_7b-deal-co-develop-new-oral-diabetes-pill-lexicon-23-percent\" target=\"_blank\">Sanofi and Lexicon Pharma sign $1.7B deal to co-develop new oral diabetes pill; Lexicon up 23% premarket</a> (Nov. 6, 2015)</li></ul><div class=\"tiny-share-widget\" data-id=\"3318060\" data-linked=\"Sanofi&#39;s planned marketing application for diabetes med propels licensor Lexicon Pharmaceuticals, up 4%\" data-tweet=\"$LXRX - Sanofi&#39;s planned marketing application for diabetes med propels licensor Lexicon Pharmaceuticals, up 4% https://seekingalpha.com/news/3318060-sanofis-planned-marketing-application-for-diabetes-med-propels-licensor-lexicon?source=tweet\" data-url=\"https://seekingalpha.com/news/3318060-sanofis-planned-marketing-application-for-diabetes-med-propels-licensor-lexicon\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:42 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318059\" data-ts=\"1513179558\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RPXC\" target=\"_blank\">RPXC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318059-rpx-up-5_6-after-takeover-offer-report\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">RPX up 5.6% after takeover offer report</a></h4><ul><li>        IAM sources say RPX (NASDAQ:<a href='https://seekingalpha.com/symbol/RPXC' title='RPX Corporation'>RPXC</a>) received a <a href=\"http://www.iam-media.com/blog/Detail.aspx?g=4ac73322-2403-4089-9f41-8e665108764a\" target=\"_blank\">takeover offe</a>r from a private consortium for $16.25 per share. &nbsp;</li><li>        The offer would value RPX at about $800M.</li><li>               RPX went public in 2011 with a $19 per share IPO price. Co-founder and CEO John Amster left the company in February after urging the board to go private.&nbsp;</li><li>               RPX shares are&nbsp;<font color='green'>up 5.6%</font>&nbsp;to $13.50.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3318059\" data-linked=\"RPX up 5.6% after takeover offer report\" data-tweet=\"$RPXC - RPX up 5.6% after takeover offer report https://seekingalpha.com/news/3318059-rpx-up-5_6-after-takeover-offer-report?source=tweet\" data-url=\"https://seekingalpha.com/news/3318059-rpx-up-5_6-after-takeover-offer-report\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:39 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318057\" data-ts=\"1513179417\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARCB\" target=\"_blank\">ARCB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318057-arcbest-hit-stifel-downgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ArcBest hit by Stifel downgrade</a></h4><ul> <li>ArcBest (NASDAQ:<a href='https://seekingalpha.com/symbol/ARCB' title='ArcBest Corporation'>ARCB</a>) falls sharply after Stifel Nicolaus issues a harsh assessment on the freight/logistics stock due to concerns on the upcoming Teamsters negotiations.</li> <li>The investment firm downgrades ArcBest to a Sell rating and sets a price target of <a href=\"https://www.streetinsider.com/Analyst+Comments/Stifel+Downgrades+ArcBest+Corp+%28ARCB%29+to+Sell%2C+Has+Tough+Negotiations+Ahead/13595227.html\" target=\"_blank\">$32</a>.</li> <li>Shares of ArcBest are <font color='red'>down 11.28%</font> to $34.20, and traded as low as $29.40 earlier.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3318057\" data-linked=\"ArcBest hit by Stifel downgrade\" data-tweet=\"$ARCB - ArcBest hit by Stifel downgrade https://seekingalpha.com/news/3318057-arcbest-hit-stifel-downgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3318057-arcbest-hit-stifel-downgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:36 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318054\" data-ts=\"1513179081\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NAT\" target=\"_blank\">NAT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318054-nordic-american-tankers-sinks-after-equity-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nordic American Tankers sinks after equity offering</a></h4><ul> <li>Nordic American Tankers (<a href='https://seekingalpha.com/symbol/NAT' title='Nordic American Tankers Limited'>NAT</a> <font color='red'>-26.4%</font>) falls sharply after the company prices the equity offering as part of its recapitalization program.</li><li>The company says that due to strong demand for shares the transaction has been upsized to $110M.</li>             <li>Nordic agreed to sell 40M shares at a public offering price of $2.75 per share.</li><li>Source: <a href=\"https://seekingalpha.com/pr/17026022-nordic-american-tankers-limited-nyse-nat-launching-recapitalization-program-nat-equity\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3318054\" data-linked=\"Nordic American Tankers sinks after equity offering\" data-tweet=\"$NAT - Nordic American Tankers sinks after equity offering https://seekingalpha.com/news/3318054-nordic-american-tankers-sinks-after-equity-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3318054-nordic-american-tankers-sinks-after-equity-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:31 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>34&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318053\" data-ts=\"1513179058\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMD\" target=\"_blank\">AMD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318053-baidu-will-use-amd-epyc-in-global-data-centers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Baidu will use AMD EPYC in global data centers</a></h4><ul><li>        AMD (NASDAQ:<a href='https://seekingalpha.com/symbol/AMD' title='Advanced Micro Devices, Inc.'>AMD</a>) and Baidu (NASDAQ:<a href='https://seekingalpha.com/symbol/BIDU' title='Baidu, Inc.'>BIDU</a>) <a href=\"http://ir.amd.com/phoenix.zhtml?c=74093&amp;p=irol-newsArticle&amp;ID=2322511\" target=\"_blank\">announce</a> the availability of the AMD EPYC processor for Baidu customers seeking AI, big data, or cloud computing services.</li><li>                  Baidu plans to expand use of EPYC across its global data centers starting in Q1.    </li><li>               AMD shares are&nbsp;<font color='green'>up 1.9%</font>.&nbsp;</li><li>               Baidu shares are&nbsp;<font color='green'>up 1%.</font>&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3316498-amd-confirms-working-qualcomm-always-connected-pcs\" target=\"_blank\">AMD confirms working with Qualcomm on Always Connected PCs</a> (Dec. 5)</li></ul><div class=\"tiny-share-widget\" data-id=\"3318053\" data-linked=\"Baidu will use AMD EPYC in global data centers\" data-tweet=\"$AMD $AMD $BIDU - Baidu will use AMD EPYC in global data centers https://seekingalpha.com/news/3318053-baidu-will-use-amd-epyc-in-global-data-centers?source=tweet\" data-url=\"https://seekingalpha.com/news/3318053-baidu-will-use-amd-epyc-in-global-data-centers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>88&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318052\" data-ts=\"1513179039\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318052-eia-petroleum-inventories\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">EIA Petroleum Inventories</a></h4><ul>     <li><a href=\"http://ir.eia.gov/wpsr/wpsrsummary.pdf\" target=\"_blank\">EIA Petroleum Inventories</a>: Crude <strong>-5.1M </strong>barrels vs. -3.8M consensus, -5.6M last week.</li><li>Gasoline <strong>+5.7M</strong> barrels vs. +2.5M consensus, +6.8M last week.</li><li>Distillates <strong>-1.4M</strong> barrels vs. +1.0M consensus, +1.7M last week.</li><li>Futures&nbsp;<font color='green'>+0.23%</font>&nbsp;to $57.27.</li><li>ETFs:<a href='https://seekingalpha.com/symbol/USO' title='The United States Oil ETF, LP'>USO</a>, <a href='https://seekingalpha.com/symbol/OIL' title='iPath S&P Crude Oil Total Return Index ETN'>OIL</a>, <a href='https://seekingalpha.com/symbol/UCO' title='ProShares Ultra Bloomberg Crude Oil ETF'>UCO</a>, <a href='https://seekingalpha.com/symbol/SCO' title='ProShares UltraShort Bloomberg Crude Oil ETF'>SCO</a>, <a href='https://seekingalpha.com/symbol/BNO' title='The United States Brent Oil ETF, LP'>BNO</a>, <a href='https://seekingalpha.com/symbol/DTO' title='DB Crude Oil Double Short ETN'>DTO</a>, <a href='https://seekingalpha.com/symbol/DBO' title='PowerShares DB Oil ETF'>DBO</a>, <a href='https://seekingalpha.com/symbol/USL' title='The United States 12 Month Oil ETF, LP'>USL</a>, <a href='https://seekingalpha.com/symbol/DNO' title='The United States Short Oil ETF, LP'>DNO</a>, <a href='https://seekingalpha.com/symbol/SZO' title='DB Crude Oil Short ETN'>SZO</a>, <a href='https://seekingalpha.com/symbol/OLO' title='DB Crude Oil Long ETN'>OLO</a>, <a href='https://seekingalpha.com/symbol/OLEM' title='iPath Pure Beta Crude Oil ETN'>OLEM</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3318052\" data-linked=\"EIA Petroleum Inventories\" data-tweet=\"$USO $OIL $UCO - EIA Petroleum Inventories https://seekingalpha.com/news/3318052-eia-petroleum-inventories?source=tweet\" data-url=\"https://seekingalpha.com/news/3318052-eia-petroleum-inventories\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>79&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318050\" data-ts=\"1513178672\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IPG\" target=\"_blank\">IPG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318050-interpublic-lower-2-after-jefferies-downgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Interpublic lower by more than 2% after Jefferies downgrade</a></h4><ul><li>After a number of years of trimming fat, there's not a lot of room for additional margin expansion next year, says analyst John Janedis, downgrading Interpublic Group (<a href='https://seekingalpha.com/symbol/IPG' title='Interpublic Group of Companies Inc.'>IPG</a> <font color='red'>-2.7%</font>) to Hold from Buy. The price target is cut to $20 from $24 (shares currently at $19.93).</li><li>Alongside, Janedis and team trim their price target on Omnicom (<a href='https://seekingalpha.com/symbol/OMC' title='Omnicom Group Inc.'>OMC</a> <font color='red'>-1.2%</font>) to $72 from $82 (currently $73.68), expecting below-trend organic growth in North America next year thanks to increased competition, and the shift of ad dollars to in-house and digital platforms.</li><li>Source: Bloomberg's Jeremy Cooke</li></ul><div class=\"tiny-share-widget\" data-id=\"3318050\" data-linked=\"Interpublic lower by more than 2% after Jefferies downgrade\" data-tweet=\"$IPG $IPG $OMC - Interpublic lower by more than 2% after Jefferies downgrade https://seekingalpha.com/news/3318050-interpublic-lower-2-after-jefferies-downgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3318050-interpublic-lower-2-after-jefferies-downgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318049\" data-ts=\"1513178359\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BETR\" target=\"_blank\">BETR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318049-amplify-snack-brands-rallies-on-m-speculation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amplify Snack Brands rallies on M&amp;A speculation</a></h4><ul> <li>Amplify Snack Brands (NYSE:<a href='https://seekingalpha.com/symbol/BETR' title='Amplify Snack Brands'>BETR</a>) <font color='green'>jumps 8.9%</font> after Oppenheimer calls the food stock an attractive takeover candidate .</li> <li>The Oppenheimer team met with Amplify's management yesterday.</li> <li>The investment firm keeps a Market Perform rating due to a \"mixed\" view on the near-term earnings prospects for Amplify.</li><li>Sources: Bloomberg, CNBC</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3318049\" data-linked=\"Amplify Snack Brands rallies on M&amp;A speculation\" data-tweet=\"$BETR $BETR-OLD - Amplify Snack Brands rallies on M&amp;A speculation https://seekingalpha.com/news/3318049-amplify-snack-brands-rallies-on-m-speculation?source=tweet\" data-url=\"https://seekingalpha.com/news/3318049-amplify-snack-brands-rallies-on-m-speculation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318046\" data-ts=\"1513177598\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JD\" target=\"_blank\">JD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318046-jd-complus-3_2-stifel-re-ups-buy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">JD.com +3.2% as Stifel re-ups at Buy</a></h4><ul>   <li>JD.com (NASDAQ:<a href='https://seekingalpha.com/symbol/JD' title='JD.com'>JD</a>) is <font color='green'>up 3.2%</font> in U.S. trading after being restarted at Buy by Stifel.</li>    <li>With China's e-commerce market barreling toward $1 trillion in sales by 2019, the stock's set to be one of \"two big winners,\" along with Alibaba (NYSE:<a href='https://seekingalpha.com/symbol/BABA' title='Alibaba Group Holding Limited'>BABA</a>), says analyst Scott Devitt.</li>    <li>JD's differentiator is logistics, he says, and it has an opportunity to monetize a third-party marketplace with value-added services.</li>    <li>He has a price target of $48, implying 21% upside from today's higher price.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3318046\" data-linked=\"JD.com +3.2% as Stifel re-ups at Buy\" data-tweet=\"$JD $JD $BABA - JD.com +3.2% as Stifel re-ups at Buy https://seekingalpha.com/news/3318046-jd-complus-3_2-stifel-re-ups-buy?source=tweet\" data-url=\"https://seekingalpha.com/news/3318046-jd-complus-3_2-stifel-re-ups-buy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:06 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>38&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318037\" data-ts=\"1513176397\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MELI\" target=\"_blank\">MELI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318037-mercadolibreplus-6-after-piper-jaffray-nod\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MercadoLibre +6% after Piper Jaffray nod</a></h4><ul> <li>MercadoLibre (NASDAQ:<a href='https://seekingalpha.com/symbol/MELI' title='MercadoLibre, Inc.'>MELI</a>) is an early mover after Piper Jaffray <a href=\"https://twitter.com/RatingsNetwork/status/940921917640531968\" target=\"_blank\">lifts</a> its price target on the e-commerce player to $330.</li> <li>Piper keeps an Overweighty rating on MELI.</li> <li>Shares of MercadoLibre are&nbsp;<font color='green'>up 6.35%</font>&nbsp;to $314.29 vs. a 52-week trading range of $150.29 to $318.58.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3318037\" data-linked=\"MercadoLibre +6% after Piper Jaffray nod\" data-tweet=\"$MELI - MercadoLibre +6% after Piper Jaffray nod https://seekingalpha.com/news/3318037-mercadolibreplus-6-after-piper-jaffray-nod?source=tweet\" data-url=\"https://seekingalpha.com/news/3318037-mercadolibreplus-6-after-piper-jaffray-nod\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:46 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318031\" data-ts=\"1513174899\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CAPR\" target=\"_blank\">CAPR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318031-capricor-announces-new-u-s-patent-covering-capminus-2003-shares-ahead-28-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Capricor announces new U.S. patent covering CAP-2003; shares ahead 28% premarket</a></h4><ul><li>Thinly traded nano cap Capricor Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/CAPR' title='Capricor Therapeutics, Inc.'>CAPR</a>) jumps&nbsp;<font color='green'>28%</font>&nbsp;premarket on robust volume in response to its <a href=\"https://seekingalpha.com/pr/17025679-capricor-therapeutics-announces-issuance-key-u-s-patent-exosome-technology\" target=\"_blank\">announcement </a>that the USPTO has issued Patent No. 9,828,603, a composition of matter patent covering pipeline candidate CAP-2003, in development for the treatment of fibrotic diseases and inflammation.</li><li><a href=\"http://capricor.com/exosomes/\" target=\"_blank\">CAP-2003</a> is a regenerative medicine therapy consisting of exosomes isolated from the company's cardiosphere-derived cells. Exosomes, nano-sized membrane-enclosed vesicles secreted by cells that contain proteins, RNAs and microDNAs, act as messengers to regulate cellular processes.</li><li>The patent was assigned to Cedars-Sinai Medical Center which granted Capricor exclusive global rights to the technology.</li></ul><div class=\"tiny-share-widget\" data-id=\"3318031\" data-linked=\"Capricor announces new U.S. patent covering CAP-2003; shares ahead 28% premarket\" data-tweet=\"$CAPR - Capricor announces new U.S. patent covering CAP-2003; shares ahead 28% premarket https://seekingalpha.com/news/3318031-capricor-announces-new-u-s-patent-covering-capminus-2003-shares-ahead-28-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3318031-capricor-announces-new-u-s-patent-covering-capminus-2003-shares-ahead-28-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:21 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318030\" data-ts=\"1513174764\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CY\" target=\"_blank\">CY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318030-susquehanna-initiates-cypress-semi\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Susquehanna initiates Cypress Semi</a></h4><ul><li>        Susquehanna <a href=\"https://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;source=web&amp;cd=1&amp;cad=rja&amp;uact=8&amp;ved=0ahUKEwiejtnrkofYAhUD74MKHS5GD0EQFggnMAA&amp;url=https%3A%2F%2Fwww.streetinsider.com%2FNew%2BCoverage%2FSusquehanna%2BStarts%2BCypress%2BSemi%2B%28CY%29%2Bat%2BPositive%2F13593964.html&amp;usg=AOvVaw0RKMZxISfexm5yuDk54Y0z\" target=\"_blank\">initiates</a> Cypress Semi (NASDAQ:<a href='https://seekingalpha.com/symbol/CY' title='Cypress Semiconductor Corporation'>CY</a>) at a Positive rating and $20 price target.</li><li>                  The price target implies a 31% upside on yesterday&rsquo;s close.    </li><li>               Cypress Semi shares are&nbsp;<font color='green'>up 33%</font>&nbsp;YTD and&nbsp;<font color='green'>up 0.07%</font>&nbsp;premarket.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3315668-suntrust-downgrades-cypress-semi-lowers-price-target\" target=\"_blank\">SunTrust downgrades Cypress Semi, lowers price target</a> (Dec. 1)</li></ul><div class=\"tiny-share-widget\" data-id=\"3318030\" data-linked=\"Susquehanna initiates Cypress Semi\" data-tweet=\"$CY - Susquehanna initiates Cypress Semi https://seekingalpha.com/news/3318030-susquehanna-initiates-cypress-semi?source=tweet\" data-url=\"https://seekingalpha.com/news/3318030-susquehanna-initiates-cypress-semi\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318029\" data-ts=\"1513174663\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318029-premarket-losers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/HMNY' title='Helios and Matheson Analytics, Inc.'>HMNY</a>&nbsp;<font color='red'>-37%</font>&nbsp;after <a href=\"https://seekingalpha.com/news/3317998-helios-matheson-minus-21-percent-share-offering-rattles-investors\" target=\"_blank\">share offering</a> rattles investors.</li><li><a href='https://seekingalpha.com/symbol/NAT' title='Nordic American Tankers Limited'>NAT</a>&nbsp;<font color='red'>-20%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3317855-nordic-american-tankers-announces-public-offering-shares\" target=\"_blank\">announcing</a> public offering of shares.</li><li><a href='https://seekingalpha.com/symbol/RIOT' title='Riot Blockchain, Inc.'>RIOT</a>&nbsp;<font color='red'>-10%</font>&nbsp;on South Korea considering <a href=\"https://seekingalpha.com/news/3317927-south-korea-considers-crypto-tax\" target=\"_blank\">crypto tax</a>.</li><li><a href='https://seekingalpha.com/symbol/NBLX' title='Noble Midstream Partners LP'>NBLX</a>&nbsp;<font color='red'>-9%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3317867-noble-midstream-partners-forms-jv-buy-dj-basin-saddle-butte-pipeline\" target=\"_blank\">forming</a> JV&nbsp;to buy DJ Basin Saddle Butte pipeline.</li><li><a href='https://seekingalpha.com/symbol/LITE' title='Lumentum Holdings Inc.'>LITE</a>&nbsp;<font color='red'>-9%</font>&nbsp;on Apple (NASDAQ:<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a>) <a href=\"https://seekingalpha.com/news/3317967-apple-invests-390m-finisar\" target=\"_blank\">investing</a> $390M in Finisar (NASDAQ:<a href='https://seekingalpha.com/symbol/FNSR' title='Finisar Corporation'>FNSR</a>).</li><li><a href='https://seekingalpha.com/symbol/PAY' title='VeriFone Systems, Inc.'>PAY</a>&nbsp;<font color='red'>-9%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3317853-verifone-systems-beats-0_01-beats-revenue\" target=\"_blank\">Q4 earnings</a>.</li><li><a href='https://seekingalpha.com/symbol/PTI' title='Proteostasis Therapeutics'>PTI</a>&nbsp;<font color='red'>-7%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3317881-proteostasis-launches-7m-share-stock-offering-shares-8-percent-hours\" target=\"_blank\">launching</a> 7M-share stock offering.</li><li><a href='https://seekingalpha.com/symbol/NTLA' title='Intellia Therapeutics'>NTLA</a>&nbsp;<font color='red'>-6%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3317822-crispr-cas9-gene-editing-players-sell-much-4-percent\" target=\"_blank\">article</a> published in EurekAlert.</li><li><a href='https://seekingalpha.com/symbol/FATE' title='Fate Therapeutics, Inc.'>FATE</a>&nbsp;<font color='red'>-6%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3318002-fate-therapeutics-prices-stock-offering-4_20-shares-5-percent-premarket\" target=\"_blank\">pricing</a> stock offering at $4.20.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3318029\" data-linked=\"Premarket Losers as of 9:05 am\" data-tweet=\"$HMNY $NAT $RIOT - Premarket Losers as of 9:05 am https://seekingalpha.com/news/3318029-premarket-losers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3318029-premarket-losers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318027\" data-ts=\"1513174204\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318027-premarket-gainers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am</a></h4><ul> <li><a href='https://seekingalpha.com/symbol/DPW' title='DPW Holdings, Inc.'>DPW</a> <font color='green'>+26%</font> on launching <a href=\"https://seekingalpha.com/news/3317978-digital-power-launches-crypto-mining-division-shares-30-percent\" target=\"_blank\">crypto mining division</a>.</li><li><a href='https://seekingalpha.com/symbol/CAPR' title='Capricor Therapeutics, Inc.'>CAPR</a> <font color='green'>+25%</font> on issuing <a href=\"https://seekingalpha.com/pr/17025679-capricor-therapeutics-announces-issuance-key-u-s-patent-exosome-technology\" target=\"_blank\">US patent</a> on Exosome Technology</li><li><a href='https://seekingalpha.com/symbol/FNSR' title='Finisar Corporation'>FNSR</a> <font color='green'>+25%</font> on <a href=\"https://seekingalpha.com/news/3317967-apple-invests-390m-finisar\" target=\"_blank\">$390M investment</a> from Apple (NASDAQ:<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a>).</li><li><a href='https://seekingalpha.com/symbol/CHFS' title='CHF Solutions, Inc.'>CHFS</a> <font color='green'>+14%</font> on <a href=\"https://seekingalpha.com/pr/17025646-chf-solutions-signs-international-distribution-services-agreement-singapore-based-transmedic\" target=\"_blank\">signing distribution agreement</a> with TRANSMEDIC.</li><li><a href='https://seekingalpha.com/symbol/ANY' title='Sphere 3D Corp.'>ANY</a> <font color='green'>+13%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3318027\" data-linked=\"Premarket Gainers as of 9:05 am\" data-tweet=\"$DPW $CAPR $FNSR - Premarket Gainers as of 9:05 am https://seekingalpha.com/news/3318027-premarket-gainers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3318027-premarket-gainers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:10 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318026\" data-ts=\"1513174192\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EPIX\" target=\"_blank\">EPIX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318026-essa-pharma-prices-stock-offering-0_20\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ESSA Pharma prices stock offering at $0.20</a></h4><ul><li>ESSA Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/EPIX' title='ESSA Pharma, Inc.'>EPIX</a>) <a href=\"https://seekingalpha.com/pr/17025843-essa-pharma-announces-pricing-previously-announced-equity-offering\" target=\"_blank\">prices </a>its \"best efforts\" offering of common stock at $0.20 per share. Its Canadian agent has the option to purchase additional shares up to 15% of the shares offered. Net proceeds will fund ongoing development of its next-generation Aniten compounds.</li><li>Yesterday's close was $0.218.</li><li>Shares will resume trading at 9:50 am ET.</li></ul><div class=\"tiny-share-widget\" data-id=\"3318026\" data-linked=\"ESSA Pharma prices stock offering at $0.20\" data-tweet=\"$EPIX - ESSA Pharma prices stock offering at $0.20 https://seekingalpha.com/news/3318026-essa-pharma-prices-stock-offering-0_20?source=tweet\" data-url=\"https://seekingalpha.com/news/3318026-essa-pharma-prices-stock-offering-0_20\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:09 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318025\" data-ts=\"1513174152\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BITA\" target=\"_blank\">BITA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318025-bitauto-holdingsplus-2_5-morgan-stanley-joins-overweight-club\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bitauto Holdings +2.5% as Morgan Stanley joins Overweight club</a></h4><ul>   <li>Bitauto Holdings ADRs (NYSE:<a href='https://seekingalpha.com/symbol/BITA' title='Bitauto Holdings Limited'>BITA</a>) are <font color='green'>up 2.5%</font> premarket after getting a new Overweight rating from Morgan Stanley.</li>    <li>That joins an exclusively bullish chorus on the stock, with seven previous Buys marking the only other ratings, Bloomberg notes.</li>    <li>Morgan Stanley has a (below-average) price target of $45, implying 54% upside.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3318025\" data-linked=\"Bitauto Holdings +2.5% as Morgan Stanley joins Overweight club\" data-tweet=\"$BITA - Bitauto Holdings +2.5% as Morgan Stanley joins Overweight club https://seekingalpha.com/news/3318025-bitauto-holdingsplus-2_5-morgan-stanley-joins-overweight-club?source=tweet\" data-url=\"https://seekingalpha.com/news/3318025-bitauto-holdingsplus-2_5-morgan-stanley-joins-overweight-club\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:09 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318019\" data-ts=\"1513173826\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARGX\" target=\"_blank\">ARGX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318019-argenx-updates-public-offering-upto-3_5m-adss-in-u-s\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Argenx updates public offering upto 3.5M ADSs in U.S.</a></h4><ul><li>Argenx (NASDAQ:<a href='https://seekingalpha.com/symbol/ARGX' title='Argenx SE'>ARGX</a>) <a href=\"http://www.argen-x.com/en-GB/news-internal/argenx-announces-size-of-proposed-public-offering-in-the-united-states-updated-to-35-million-adss/30168/\" target=\"_blank\">announces</a> that it has updated the number of ADSs in its U.S. public offering to 3.5M ADSs yielding <a href=\"http://www.argen-x.com/en-GB/news-internal/argenx-announces-launch-of-proposed-public-offering-in-the-united-states/30167/\" target=\"_blank\">$150M</a>. Each of the ADSs represents one ordinary share.</li><li>Underwriters are granted a 30-day option to purchase additional ADSs, provided it does not exceed 15% of the ADSs sold in the Offering.</li><li>Shares are down&nbsp;<font color='red'>4%</font>&nbsp;premarket on robust volume. Yesterday's close was $55.</li></ul><div class=\"tiny-share-widget\" data-id=\"3318019\" data-linked=\"Argenx updates public offering upto 3.5M ADSs in U.S.\" data-tweet=\"$ARGX - Argenx updates public offering upto 3.5M ADSs in U.S. https://seekingalpha.com/news/3318019-argenx-updates-public-offering-upto-3_5m-adss-in-u-s?source=tweet\" data-url=\"https://seekingalpha.com/news/3318019-argenx-updates-public-offering-upto-3_5m-adss-in-u-s\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:03 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318022\" data-ts=\"1513173681\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MDXG\" target=\"_blank\">MDXG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318022-mimedx-sees-revenues-high-387m-in-2018-shares-up-1-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MiMedx sees revenues as high as $387M in 2018; shares up 1% premarket</a></h4><ul><li>MiMedx (<a href='https://seekingalpha.com/symbol/MDXG' title='MiMedx Group Inc.'>OTC:MDXG</a>) is up&nbsp;<font color='green'>1%</font>&nbsp;premarket on light volume on the heels of its <a href=\"https://seekingalpha.com/pr/17025559-mimedx-forecasts-2018-revenue-range-383-million-387-million\" target=\"_blank\">announcement </a>of 2018 guidance.</li><li>Revenue: $383M - 387M; EPS: $0.30 - 0.35; non-GAAP EPS: $0.45 - 0.50.</li><li>Gross margin should be greater than 2017.</li><li>Salesforce to be expanded by ~60, for a total of ~440. Additional management to be hired in Canada and Middle East.</li><li>Management will host a conference call today at 10:30 am ET to discuss its outlook.</li></ul><div class=\"tiny-share-widget\" data-id=\"3318022\" data-linked=\"MiMedx sees revenues as high as $387M in 2018; shares up 1% premarket\" data-tweet=\"$MDXG - MiMedx sees revenues as high as $387M in 2018; shares up 1% premarket https://seekingalpha.com/news/3318022-mimedx-sees-revenues-high-387m-in-2018-shares-up-1-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3318022-mimedx-sees-revenues-high-387m-in-2018-shares-up-1-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318017\" data-ts=\"1513173412\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KMT\" target=\"_blank\">KMT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318017-bmo-capital-lifts-pt-of-kennametal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BMO Capital lifts PT of Kennametal</a></h4><ul><li>Kennametal (NYSE:<a href='https://seekingalpha.com/symbol/KMT' title='Kennametal Inc.'>KMT</a>) <font color='green'>+1.5%</font> premarket after BMO Capital <a href=\"https://www.thelincolnianonline.com/2017/12/13/bmo-capital-markets-increases-kennametal-kmt-price-target-to-52-00.html\" target=\"_blank\">raised</a> its price target on the stock to $52 (from $45) and kept its Market Perform rating on shares.</li></ul><div class=\"tiny-share-widget\" data-id=\"3318017\" data-linked=\"BMO Capital lifts PT of Kennametal\" data-tweet=\"$KMT - BMO Capital lifts PT of Kennametal https://seekingalpha.com/news/3318017-bmo-capital-lifts-pt-of-kennametal?source=tweet\" data-url=\"https://seekingalpha.com/news/3318017-bmo-capital-lifts-pt-of-kennametal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:56 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318016\" data-ts=\"1513173276\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318016-yields-dip-on-slow-cpi-print\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Yields dip on slow CPI print</a></h4><ul><li><a href=\"https://seekingalpha.com/news/3318001-consumer-prices-match-estimates-0_4-percent-gain\" target=\"_blank\">Headline CPI matched</a> expectations, rising 0.4% in November alongside a sizable jump in gasoline prices.</li><li>Core inflation, however, gained just 0.1% vs. 0.2% expected. On a year-over-year basis, core CPI is now running at 1.7% vs. 1.8% a month earlier.</li><li>While the news is likely to give fuel to those at the Fed wishing to pause rate hikes until inflation picks up, it's probably not going to halt what almost all expect to be another boost in short-term rates at the close of today's FOMC meeting.</li><li>The 10-year yield has dropped five basis points since the CPI number hit, now down 3.5 bps on the session to 2.373%. <a href='https://seekingalpha.com/symbol/TLT' title='iShares 20+ Year Treasury Bond ETF'>TLT</a>&nbsp;<font color='green'>+0.4%</font>, <a href='https://seekingalpha.com/symbol/TBT' title='ProShares UltraShort 20+ Year Treasury ETF'>TBT</a>&nbsp;<font color='red'>-0.8%</font></li><li>ETFs: <a href='https://seekingalpha.com/symbol/TLT' title='iShares 20+ Year Treasury Bond ETF'>TLT</a>, <a href='https://seekingalpha.com/symbol/TBT' title='ProShares UltraShort 20+ Year Treasury ETF'>TBT</a>, <a href='https://seekingalpha.com/symbol/TMV' title='Direxion Daily 20+ Year Treasury Bear 3x Shares ETF'>TMV</a>, <a href='https://seekingalpha.com/symbol/TBF' title='ProShares Short 20+ Year Treasury ETF'>TBF</a>, <a href='https://seekingalpha.com/symbol/EDV' title='Vanguard Extended Duration Treasury ETF'>EDV</a>, <a href='https://seekingalpha.com/symbol/TMF' title='Direxion Daily 30-Year Treasury Bull 3x Shares ETF'>TMF</a>, <a href='https://seekingalpha.com/symbol/TTT' title='ProShares UltraPro Short 20+ Year Treasury ETF'>TTT</a>, <a href='https://seekingalpha.com/symbol/ZROZ' title='PIMCO 25+ Year Zero Coupon U.S. Treasury Index ETF'>ZROZ</a>, <a href='https://seekingalpha.com/symbol/VGLT' title='Vanguard Long-Term Government Bond Index ETF'>VGLT</a>, <a href='https://seekingalpha.com/symbol/TLH' title='iShares 10-20 Year Treasury Bond ETF'>TLH</a>, <a href='https://seekingalpha.com/symbol/UBT' title='ProShares Ultra 20+ Year Treasury ETF'>UBT</a>, <a href='https://seekingalpha.com/symbol/TLO' title='SPDR Barclays Long Term Treasury ETF'>TLO</a>, <a href='https://seekingalpha.com/symbol/DLBS' title='iPath U.S. Treasury Long Bond Bear ETN'>DLBS</a>, <a href='https://seekingalpha.com/symbol/VUSTX' title='Vanguard Long Term Treasury Fund Inv'>VUSTX</a>, <a href='https://seekingalpha.com/symbol/TYBS' title='Direxion Daily 20+ Year Treasury Bear 1x Shares ETF'>TYBS</a>, <a href='https://seekingalpha.com/symbol/DLBL' title='iPath U.S. Treasury Long Bond Bull ETN'>DLBL</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3318016\" data-linked=\"Yields dip on slow CPI print\" data-tweet=\"$TLT $TBT $TMV - Yields dip on slow CPI print https://seekingalpha.com/news/3318016-yields-dip-on-slow-cpi-print?source=tweet\" data-url=\"https://seekingalpha.com/news/3318016-yields-dip-on-slow-cpi-print\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:54 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318007\" data-ts=\"1513173170\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CRL\" target=\"_blank\">CRL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318007-premarket-analyst-action-healthcare\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket analyst action - healthcare</a></h4><ul><li>Charles River Laboratories (NYSE:<a href='https://seekingalpha.com/symbol/CRL' title='Charles River Laboratories International, Inc.'>CRL</a>) initiated with Buy rating and $120 (14% upside) price target by Argus Research.</li><li>Catalent (NYSE:<a href='https://seekingalpha.com/symbol/CTLT' title='Catalent'>CTLT</a>) initiated with Outperform rating and $46 (15% upside) price target by RBC Capital Markets.</li><li>MEDNAX (NYSE:<a href='https://seekingalpha.com/symbol/MD' title='Mednax, Inc.'>MD</a>) initiated with Overweight rating and $58 (12% upside) price target by Piper Jaffray.</li><li>Envision Healthcare (NYSE:<a href='https://seekingalpha.com/symbol/EVHC' title='Envision Healthcare Holdings'>EVHC</a>) initiated with Neutral rating and $35 (5% upside) price target by Piper Jaffray.</li><li>Intercept Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ICPT' title='Intercept Pharmaceuticals'>ICPT</a>) and Vertex Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/VRTX' title='Vertex Pharmaceuticals Incorporated'>VRTX</a>) initiated with Strong Buy ratings by Deutsche Bank.</li><li>Audentes Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/BOLD' title='Audentes Therapeutics'>BOLD</a>) resumed with Overweight rating and $36 (31% upside) price target by Piper Jaffray.</li><li>DENTSPLY SIRONA (NASDAQ:<a href='https://seekingalpha.com/symbol/XRAY' title='DENTSPLY SIRONA, Inc'>XRAY</a>) upgraded to Overweight by JPMorgan.</li><li>Bluebird bio (NASDAQ:<a href='https://seekingalpha.com/symbol/BLUE' title='bluebird bio, Inc.'>BLUE</a>) downgraded to Hold with a $200 (5% upside) price target by Maxim Group.</li><li>Accelerate Diagnostics (NASDAQ:<a href='https://seekingalpha.com/symbol/AXDX' title='Accelerate Diagnostics, Inc.'>AXDX</a>) downgraded to Neutral by BTIG Research.</li><li>Genomic Health (NASDAQ:<a href='https://seekingalpha.com/symbol/GHDX' title='Genomic Health, Inc.'>GHDX</a>) downgraded to Underweight with a $25 (17% downside risk) by JPMorgan citing soft U.S. invasive breast cancer market and slower-than-expected reimbursement rate.</li><li>Accuray (NASDAQ:<a href='https://seekingalpha.com/symbol/ARAY' title='Accuray Incorporated'>ARAY</a>) downgraded to Underweight by JPMorgan citing lack of consistency in quarterly earnings, competitive pressures and execution issues. $8 price target removed. Shares down&nbsp;<font color='red'>6%&nbsp;</font>premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3318007\" data-linked=\"Premarket analyst action - healthcare\" data-tweet=\"$CRL $CRL $CTLT - Premarket analyst action - healthcare https://seekingalpha.com/news/3318007-premarket-analyst-action-healthcare?source=tweet\" data-url=\"https://seekingalpha.com/news/3318007-premarket-analyst-action-healthcare\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:52 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318011\" data-ts=\"1513172425\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVDA\" target=\"_blank\">NVDA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318011-nvidia-partners-japanese-builder-for-safer-sites\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nvidia partners with Japanese builder for safer sites</a></h4><ul><li>        Nvidia (NASDAQ:<a href='https://seekingalpha.com/symbol/NVDA' title='NVIDIA Corporation'>NVDA</a>) <a href=\"https://www.reuters.com/article/nvidia-komatsu/nvidia-to-partner-with-japans-komatsu-to-bring-ai-to-building-sites-idUSL3N1OD3WY?feedType=RSS&amp;feedName=companyNews&amp;utm_source=feedburner&amp;utm_medium=feed&amp;utm_campaign=Feed%3A+reuters%2FcompanyNews+%28News+%2F+US+%2F+Company+News%29\" target=\"_blank\">will partner</a> with Japanese construction company Komatsu Ltd.</li><li>               Komatsu will use Nvidia&rsquo;s GPUs to visualize and analyze building sites for safety purposes.&nbsp;</li><li>               Future construction equipment will use AI to &ldquo;perceive their surroundings and be continuously alert, helping operators work more efficiently and safely,&rdquo; according to Nvidia CEO Jensen Huang. &nbsp;&nbsp;</li><li>Nvidia shares are&nbsp;<font color='green'>up 0.2%</font>&nbsp;premarket.&nbsp; &nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3317729-nvidia-ex-facebook-exec-implies-caution\" target=\"_blank\">Nvidia down after ex-Facebook exec implies caution</a> (Dec. 12)</li></ul><div class=\"tiny-share-widget\" data-id=\"3318011\" data-linked=\"Nvidia partners with Japanese builder for safer sites\" data-tweet=\"$NVDA - Nvidia partners with Japanese builder for safer sites https://seekingalpha.com/news/3318011-nvidia-partners-japanese-builder-for-safer-sites?source=tweet\" data-url=\"https://seekingalpha.com/news/3318011-nvidia-partners-japanese-builder-for-safer-sites\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:40 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>46&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318010\" data-ts=\"1513172393\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMTD\" target=\"_blank\">AMTD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318010-ameritrade-down-nearly-2-backers-cash-out\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ameritrade down nearly 2% as backers cash out</a></h4><ul><li>The company last night announced an offering of 27.7M shares by the Riney family. Underwriter Goldman Sachs expects to offer the shares at $51.50 each. TD Ameritrade (NASDAQ:<a href='https://seekingalpha.com/symbol/AMTD' title='TD Ameritrade Holding Corporation'>AMTD</a>) will receive no proceeds from the sale.</li><li>Source: <a href=\"https://seekingalpha.com/pr/17025787-td-ameritrade-announces-pricing-secondary-offering-common-stock\" target=\"_blank\">Press Release</a></li><li>The stock's&nbsp;<font color='red'>down 1.9%</font>&nbsp;premarket to $51.69.</li></ul><div class=\"tiny-share-widget\" data-id=\"3318010\" data-linked=\"Ameritrade down nearly 2% as backers cash out\" data-tweet=\"$AMTD - Ameritrade down nearly 2% as backers cash out https://seekingalpha.com/news/3318010-ameritrade-down-nearly-2-backers-cash-out?source=tweet\" data-url=\"https://seekingalpha.com/news/3318010-ameritrade-down-nearly-2-backers-cash-out\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:39 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318004\" data-ts=\"1513172144\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MNGA\" target=\"_blank\">MNGA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318004-magnegas-expands-eu-consulting-contract\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MagneGas expands EU consulting contract</a></h4><ul><li>MagneGas (NASDAQ:<a href='https://seekingalpha.com/symbol/MNGA' title='MagneGas Corporation'>MNGA</a>) <font color='green'>+11.6%</font> premarket after <a href=\"https://seekingalpha.com/pr/17025605-magnegas-expands-european-consulting-contract-50-percent-750000\" target=\"_blank\">announcing</a> an amendment to its previously announced $500K consulting agreement with a European partner.</li><li>The contract was increased by 50% to $750K for the purpose of accelerating the commercialization of MagneGas2 as a renewable cutting fuel for the European market.</li></ul><div class=\"tiny-share-widget\" data-id=\"3318004\" data-linked=\"MagneGas expands EU consulting contract\" data-tweet=\"$MNGA $TRNX - MagneGas expands EU consulting contract https://seekingalpha.com/news/3318004-magnegas-expands-eu-consulting-contract?source=tweet\" data-url=\"https://seekingalpha.com/news/3318004-magnegas-expands-eu-consulting-contract\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:35 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318002\" data-ts=\"1513171933\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FATE\" target=\"_blank\">FATE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318002-fate-therapeutics-prices-stock-offering-4_20-shares-down-5-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fate Therapeutics prices stock offering at $4.20; shares down 5% premarket</a></h4><ul><li>Fate Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/FATE' title='Fate Therapeutics, Inc.'>FATE</a>) eases<font color='red'> 5%</font>&nbsp;premarket, albeit on only 700 shares, in response to its <a href=\"https://seekingalpha.com/pr/17025718-fate-therapeutics-announces-pricing-public-offering-common-stock\" target=\"_blank\">public offering </a>of 9.525M shares of common stock at $4.20 per share. Underwriters over-allotment is an additional ~1.4M shares. Closing date is December 15.</li><li>Yesterday's close was $4.43.</li></ul><div class=\"tiny-share-widget\" data-id=\"3318002\" data-linked=\"Fate Therapeutics prices stock offering at $4.20; shares down 5% premarket\" data-tweet=\"$FATE - Fate Therapeutics prices stock offering at $4.20; shares down 5% premarket https://seekingalpha.com/news/3318002-fate-therapeutics-prices-stock-offering-4_20-shares-down-5-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3318002-fate-therapeutics-prices-stock-offering-4_20-shares-down-5-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:32 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317999\" data-ts=\"1513171527\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BLUE\" target=\"_blank\">BLUE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317999-bluebird-bio-prices-stock-offering-185-shares-down-2-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bluebird bio prices stock offering at $185; shares down 2% premarket</a></h4><ul><li>Bluebird bio (NASDAQ:<a href='https://seekingalpha.com/symbol/BLUE' title='bluebird bio, Inc.'>BLUE</a>) slips&nbsp;<font color='red'>2%</font>&nbsp;premarket on average volume in response to its <a href=\"https://seekingalpha.com/pr/17025405-bluebird-bio-announces-pricing-public-offering-common-stock\" target=\"_blank\">public offering</a> of ~3.2M shares of common stock at $185 per share. Underwriters over-allotment is an additional ~486K shares. Closing date is December 15.</li><li>Yesterday's close was $190.95.</li></ul><div class=\"tiny-share-widget\" data-id=\"3317999\" data-linked=\"Bluebird bio prices stock offering at $185; shares down 2% premarket\" data-tweet=\"$BLUE - Bluebird bio prices stock offering at $185; shares down 2% premarket https://seekingalpha.com/news/3317999-bluebird-bio-prices-stock-offering-185-shares-down-2-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3317999-bluebird-bio-prices-stock-offering-185-shares-down-2-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:25 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317998\" data-ts=\"1513171409\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HMNY\" target=\"_blank\">HMNY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317998-helios-and-mathesonminus-21-after-share-offering-rattles-investors\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Helios and Matheson -21% after share offering rattles investors</a></h4><ul> <li>Shares of Helios and Matheson Analytics (NASDAQ:<a href='https://seekingalpha.com/symbol/HMNY' title='Helios and Matheson Analytics, Inc.'>HMNY</a>) sink in early action after the MoviePass owner's offering of shares and warrants of an undetermined size rattles investors.</li> <li>Some investors pushed into Helios in the $11 to $12 range yesterday after the company's deal with Costco was announced.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3317756-costco-offers-movie-deal\" target=\"_blank\">Costco offers up a movie deal</a> (Dec. 12)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3317859-moviepass-owner-announces-share-offering\" target=\"_blank\">MoviePass owner announces share offering</a> (Dec. 12)</li> <li>HMNY <font color='red'>-20.63%</font> premarket to $8.00.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3317998\" data-linked=\"Helios and Matheson -21% after share offering rattles investors\" data-tweet=\"$HMNY - Helios and Matheson -21% after share offering rattles investors https://seekingalpha.com/news/3317998-helios-and-mathesonminus-21-after-share-offering-rattles-investors?source=tweet\" data-url=\"https://seekingalpha.com/news/3317998-helios-and-mathesonminus-21-after-share-offering-rattles-investors\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317978\" data-ts=\"1513169242\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DPW\" target=\"_blank\">DPW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317978-digital-power-launches-crypto-mining-division-shares-up-30\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Digital Power launches crypto mining division; shares up 30%</a></h4><ul><li>Initial strategy is to mine the top ten cryptocurrencies - Bitcoin, Ether, Bitcoin Cash, Litecoin, Dash, and Monero among them.</li><li>The company has inked a deal with IMG Networks to establish a series of global digital mining farms with a goal of developing a network of more than 10K mining machines.</li><li>Source: <a href=\"https://seekingalpha.com/pr/17025537-digital-power-corporation-creates-cryptocurrency-mining-division\" target=\"_blank\">Press Release</a></li><li><a href='https://seekingalpha.com/symbol/DPW' title='DPW Holdings, Inc.'>DPW</a>&nbsp;<font color='green'>+30.5%</font>&nbsp;premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3317978\" data-linked=\"Digital Power launches crypto mining division; shares up 30%\" data-tweet=\"$DPW - Digital Power launches crypto mining division; shares up 30% https://seekingalpha.com/news/3317978-digital-power-launches-crypto-mining-division-shares-up-30?source=tweet\" data-url=\"https://seekingalpha.com/news/3317978-digital-power-launches-crypto-mining-division-shares-up-30\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:47 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>24&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317974\" data-ts=\"1513169035\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PFE\" target=\"_blank\">PFE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317974-servier-and-pfizers-car-t-candidate-shows-positive-effect-in-two-early-stage-leukemia-studies\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Servier and Pfizer&#39;s CAR-T candidate shows positive effect in two early-stage leukemia studies; licensor Cellectis up 13% premarket</a></h4><ul><li><a href=\"https://seekingalpha.com/pr/17025374-preliminary-data-servier-pfizer-s-ucart19-product-candidate-shows-high-complete-remission\" target=\"_blank\">Preliminary results </a>from two Phase 1 clinical trials assessing Servier and Pfizer's (NYSE:<a href='https://seekingalpha.com/symbol/PFE' title='Pfizer Inc.'>PFE</a>) CAR-T candidate, UCART19, in leukemia patients showed a treatment effect. The data were presented at ASH in Atlanta.</li><li>The first study, CALM, is evaluating UCART19 in adult patients with relapsed/refractory CD-19-positive B-cell acute lymphoblastic leukemia (B-ALL). Five of seven (71%) subjects achieved molecular remission at day 28 after treatment. Molecular remission is defined as negative minimal residual disease &#40;MRD&#41; (the number of residual leukemic cells remaining after treatment). The dose of UCART19 used in the first cohort was about 1/10 of that used in most autologous CAR-T studies.</li><li>On the safety front, one mild case of acute graft-versus-host disease (GvHD) was observed. No severe neurotoxicity was observed. There was one death due to cytokine release syndrome &#40;CRS&#41; and neutropenic (abnormally low level of neutrophils) sepsis. All other cases of CRS were mild and manageable.</li><li>The second study, PALL, is assessing UCART19 in pediatric patients with high-risk relapsed/refractory B-ALL. All five children treated achieved MRD negativity enabling them to proceed to allogeneic stem cell transplant.</li><li>Only one mild case of GvHD was observed. No neurotoxicity occurred and CRSs were mostly mild and all were manageable.</li><li>Servier and Pfizer are co-developing UCART19. Servier obtained exclusive global rights from Cellectis (NASDAQ:<a href='https://seekingalpha.com/symbol/CLLS' title='Cellectis S.A.'>CLLS</a>) in November 2015.</li><li>CLLS is up&nbsp;<font color='green'>13%</font>&nbsp;premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3317974\" data-linked=\"Servier and Pfizer&#39;s CAR-T candidate shows positive effect in two early-stage leukemia studies; licensor Cellectis up 13% premarket\" data-tweet=\"$PFE $PFE $CLLS - Servier and Pfizer&#39;s CAR-T candidate shows positive effect in two early-stage leukemia studies; licensor Cellectis up 13% premarket https://seekingalpha.com/news/3317974-servier-and-pfizers-car-t-candidate-shows-positive-effect-in-two-early-stage-leukemia-studies?source=tweet\" data-url=\"https://seekingalpha.com/news/3317974-servier-and-pfizers-car-t-candidate-shows-positive-effect-in-two-early-stage-leukemia-studies\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:43 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317967\" data-ts=\"1513168763\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAPL\" target=\"_blank\">AAPL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317967-apple-invests-390m-in-finisar\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Apple invests $390M in Finisar</a></h4><ul><li>Apple&rsquo;s (NASDAQ:<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a>) Advanced Manufacturing Fund <a href=\"https://www.wsj.com/articles/apple-awards-390-million-to-face-id-tech-company-finisar-1513166918?mod=pls_whats_news_us_business_f\" target=\"_blank\">invests</a> $390M in Face ID supplier Finisar (NASDAQ:<a href='https://seekingalpha.com/symbol/FNSR' title='Finisar Corporation'>FNSR</a>).</li><li>Finisar recently began production quantity shipping of its vertical-cavity surface-emitting lasers (VCSELs), a laser technology used in the iPhone X&rsquo;s facial recognition system and in Portrait-mode pictures.</li><li>Apple plans to buy 10 times more VCSELs in Q4 than in previous quarters.</li><li>Apple&rsquo;s investment is meant to bolster domestic suppliers, speed production times, and boost R&amp;D. Finisar will remodel a 700K-square-foot plant in Texas and create 500 high-skill jobs.</li><li>Finisar shares are&nbsp;<font color='green'>up 21%</font>&nbsp;premarket.</li><li>Update: Stocks moving with the Finisar news include 3D sensor maker Lumentum (NASDAQ:<a href='https://seekingalpha.com/symbol/LITE' title='Lumentum Holdings Inc.'>LITE</a>), which is&nbsp;<font color='red'>down 5.8%</font>&nbsp;premarket. VCSEL maker II-VI (NASDAQ:<a href='https://seekingalpha.com/symbol/IIVI' title='II-VI Incorporated'>IIVI</a>) is&nbsp;<font color='green'>up 1.6%</font>. Other optical stocks: Applied Optoelectronics (NASDAQ:<a href='https://seekingalpha.com/symbol/AAOI' title='Applied Optoelectronics, Inc.'>AAOI</a>) is&nbsp;<font color='red'>down 1.4%&nbsp;</font>and Acacia Communications (NASDAQ:<a href='https://seekingalpha.com/symbol/ACIA' title='Acacia Communications'>ACIA</a>) is&nbsp;<font color='green'>up 0.03%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3317967\" data-linked=\"Apple invests $390M in Finisar\" data-tweet=\"$AAPL $AAPL $FNSR - Apple invests $390M in Finisar https://seekingalpha.com/news/3317967-apple-invests-390m-in-finisar?source=tweet\" data-url=\"https://seekingalpha.com/news/3317967-apple-invests-390m-in-finisar\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:39 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>118&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317953\" data-ts=\"1513167748\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WDC\" target=\"_blank\">WDC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317953-western-digital-updates-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Western Digital updates guidance</a></h4><ul><li>        Western Digital (NYSE:<a href='https://seekingalpha.com/symbol/WDC' title='Western Digital Corporation'>WDC</a>) <a href=\"http://files.shareholder.com/downloads/WDC/5714424391x0x966464/0AFA9BFE-D559-4C56-88C4-4D0C977001D0/Guidance_Summary.PDF\" target=\"_blank\">updates its guidance</a> following the mutual agreement with Toshiba. Q2 guidance has revenue of $5.3B (consensus: $5.28B, was: $5.2B to $5.3B) and EPS at $3.80 (consensus: $3.67, was: $3.60 to $3.80).</li><li>                  FY18 guidance has EPS over $13 (consensus: $13.18) and revenue at the high end of 4% to 8% growth or about $20.6B (consensus: $20.34B).    </li><li>               Western Digital shares are&nbsp;<font color='green'>up 3.3%</font>&nbsp;premarket.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3317894-western-digital-toshiba-announce-agreement-chip-unit-fab-6\" target=\"_blank\">Western Digital and Toshiba announce agreement on chip unit, Fab 6</a> (Dec. 12)</li></ul><div class=\"tiny-share-widget\" data-id=\"3317953\" data-linked=\"Western Digital updates guidance\" data-tweet=\"$WDC - Western Digital updates guidance https://seekingalpha.com/news/3317953-western-digital-updates-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3317953-western-digital-updates-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:22 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3317943\" data-ts=\"1513166471\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BPMC\" target=\"_blank\">BPMC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3317943-blueprint-prices-stock-offering-81\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Blueprint prices stock offering at $81</a></h4><ul><li>Blueprint Medicines (NASDAQ:<a href='https://seekingalpha.com/symbol/BPMC' title='Blueprint Medicines'>BPMC</a>) <a href=\"https://seekingalpha.com/pr/17025410-blueprint-medicines-announces-pricing-public-offering-shares-common-stock\" target=\"_blank\">prices </a>its public offering of ~3.7M common shares at $81 per share. Underwriters over-allotment is an additional ~555.6K shares. Closing date is December 15.</li><li>Yesterday's close was $81.98.</li></ul><div class=\"tiny-share-widget\" data-id=\"3317943\" data-linked=\"Blueprint prices stock offering at $81\" data-tweet=\"$BPMC - Blueprint prices stock offering at $81 https://seekingalpha.com/news/3317943-blueprint-prices-stock-offering-81?source=tweet\" data-url=\"https://seekingalpha.com/news/3317943-blueprint-prices-stock-offering-81\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:01 AM </div></div></li>","count":66,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}